0001157523-22-001011.txt : 20220803 0001157523-22-001011.hdr.sgml : 20220803 20220803163110 ACCESSION NUMBER: 0001157523-22-001011 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220803 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220803 DATE AS OF CHANGE: 20220803 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CROSS COUNTRY HEALTHCARE INC CENTRAL INDEX KEY: 0001141103 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-HELP SUPPLY SERVICES [7363] IRS NUMBER: 134066229 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-33169 FILM NUMBER: 221133125 BUSINESS ADDRESS: STREET 1: 6551 PARK OF COMMERCE BOULEVARD, N.W. CITY: BOCA RATON STATE: FL ZIP: 33487 BUSINESS PHONE: 8003472264 MAIL ADDRESS: STREET 1: 6551 PARK OF COMMERCE BOULEVARD, N.W. CITY: BOCA RATON STATE: FL ZIP: 33487 FORMER COMPANY: FORMER CONFORMED NAME: CROSS COUNTRY INC DATE OF NAME CHANGE: 20010521 8-K 1 a52798979.htm CROSS COUNTRY HEALTHCARE, INC. 8-K

UNITED STATES 
 SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549
 
 
 
FORM 8-K
 
 
 
CURRENT REPORT


Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported) August 3, 2022
 graphic
 
 
 
Cross Country Healthcare, Inc.
(Exact name of registrant as specified in its charter)
 
 

Delaware
0-33169
13-4066229
(State or Other Jurisdiction
of Incorporation)
(Commission
File Number)
(I.R.S. Employer
Identification No.)
 
6551 Park of Commerce Boulevard, N.W., Boca Raton, Florida 33487
(Address of Principal Executive Office) (Zip Code)

(561) 998-2232
(Registrant’s telephone number, including area code)

Not Applicable
(Former name or former address, if changed since last report)
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class Trading Symbol Name of each exchange on which registered
Common stock, par value $0.0001 per share
 CCRN
 The Nasdaq Stock Market LLC

 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2).
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Section 2 – Financial Information
 
Item 2.02     Results of Operations and Financial Condition
 
(a)  On August 3, 2022, Cross Country Healthcare, Inc. (“the Company”) issued a press release announcing results for the quarter ended June 30, 2022, a copy of which is attached as Exhibit 99.1 to this Current Report on Form 8-K. This information is being furnished under Item 2.02 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of such section.
Section 7 – Regulation FD
 
Item 7.01     Regulation FD Disclosure
 
Incorporated by reference is a press release issued by the Company on August 3, 2022, which is attached hereto as Exhibit 99.1. This information is being furnished under Item 7.01 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of such section.
 
Section 9 – Financial Statements and Exhibits
 
Item 9.01     Financial Statements and Exhibits
 
(d) Exhibits

 
Exhibit
Description
     
 
 
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

 
CROSS COUNTRY HEALTHCARE, INC.
     
     
 
By:
/s/ William J. Burns
   
William J. Burns
Dated:     August 3, 2022
  
Executive Vice President & Chief Financial Officer

EX-99.1 2 a52798979ex991.htm EXHIBIT 99.1
Exhibit 99.1

Cross Country Healthcare Announces Second Quarter 2022 Financial Results

BOCA RATON, Fla.--(BUSINESS WIRE)--August 3, 2022--Cross Country Healthcare, Inc. (the "Company") (Nasdaq: CCRN) today announced financial results for its second quarter ended June 30, 2022.

SELECTED FINANCIAL INFORMATION:

 

 

 

 

 

Variance

 

Variance

 

 

 

 

 

Q2 2022 vs

 

Q2 2022 vs

Dollars are in thousands, except per share amounts

Q2 2022

 

Q2 2021

 

Q1 2022

Revenue

$

753,561

 

 


 

127

 

%


 

(4

)

%

Gross profit margin*

 

22.6

 

%


 

70

 

bps


 

40

 

bps

Net income attributable to common stockholders

$

52,894

 

 


 

358

 

%


 

(15

)

%

Diluted EPS

$

1.40

 

 


$

1.09

 

 


$

(0.23

)


Adjusted EBITDA*

$

83,490

 

 


 

244

 

%


 

(14

)

%

Adjusted EBITDA margin*

 

11.1

 

%


 

380

 

bps


 

(120

)

bps

Adjusted EPS*

$

1.40

 

 


$

0.93

 

 


$

(0.30

)


Cash flows used in operations

$

18,141

 

 


 

17

 

%


 

162

 

%

* Refer to accompanying tables and discussion of non-GAAP (Generally Accepted Accounting Principles) financial measures below.

Second Quarter Business Highlights

  • Revenue and Adjusted EBITDA exceeded guidance ranges
  • Record number of professionals on assignment
  • Double-digit year-over-year growth across all lines of business
  • Adjusted EBITDA margin of 11.1%
  • Launched Intellify, our proprietary Vendor Management System for Managed Service Programs (MSPs)
  • Rise in demand throughout the quarter, especially for travel assignments
  • $50.0 million optional prepayment on the term loan

“Our second quarter 2022 results reflect continued strong performance that showcases our ongoing success in leveraging technology and our deep relationships to efficiently place professionals across the healthcare continuum. We are emerging from the pandemic as a fundamentally different company, with a comprehensive suite of technologies that position us for long-term, sustained growth across all lines of business,” said John Martins, President and Chief Executive Officer of Cross Country Healthcare. He continued, “We remain committed to our investments in people and technology, and we see a strong demand from both existing and new MSP clients setting up a solid runway for continued growth.”

Second quarter consolidated revenue was $753.6 million, an increase of 127% year-over-year and a decrease of 4% sequentially. Consolidated gross profit margin was 22.6%, up 70 basis points year-over-year and up 40 basis points sequentially. Net income attributable to common stockholders was $52.9 million compared to $11.5 million in the prior year and $62.0 million in the prior quarter. Diluted earnings per share (EPS) was $1.40 compared to $0.31 in the prior year and $1.63 in the prior quarter. Adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) was $83.5 million or 11.1% of revenue, as compared with $24.3 million or 7.3% of revenue in the prior year, and $97.4 million or 12.3% of revenue in the prior quarter. Adjusted EPS was $1.40 compared to $0.47 in the prior year and $1.70 in the prior quarter.

For the six months ended June 30, 2022, consolidated revenue was $1.5 billion, an increase of 133% year-over-year. Consolidated gross profit margin was 22.4%, up 60 basis points year-over-year. Net income attributable to common stockholders was $114.9 million, or $3.03 per diluted share, compared to $31.0 million, or $0.84 per diluted share, in the prior year. Adjusted EBITDA was $180.9 million or 11.7% of revenue, as compared with $51.0 million or 7.7% of revenue in the prior year. Adjusted EPS was $3.10 compared to $1.05 in the prior year.

Quarterly Business Segment Highlights

Nurse and Allied Staffing

Revenue was $731.4 million, an increase of 131% year-over-year and a decrease of 4% sequentially. Contribution income was $97.6 million, an increase compared to $35.3 million in the prior year and a decrease compared to $110.1 million in the prior quarter. Average field contract personnel on a full-time equivalent (FTE) basis were 13,494 as compared with 7,578 in the prior year and 13,454 in the prior quarter. Revenue per FTE per day was $591 compared to $454 in the prior year and $628 in the prior quarter. The increase in the average number of FTEs was primarily due to headcount growth in travel nurse and allied, as well as the year-over-year additional headcount resulting from the Workforce Solutions Group (WSG) acquisition in June 2021. In the second quarter of 2022, average bill rates were down in the mid-single digits as expected, but volumes were stronger as we continued to experience high demand across a wide range of specialties spanning the healthcare continuum. A spike in professionals on assignment and volume growth primarily drove the year-over-year revenue improvement.

Physician Staffing

Revenue was $22.1 million, an increase of 41% year-over-year and a decrease of 4% sequentially. Contribution income was $1.2 million, an increase compared to $0.6 million in the prior year and a decrease compared to $1.8 million in the prior quarter. Total days filled were 12,416 as compared with 9,775 in the prior year and 13,068 in the prior quarter. Revenue per day filled was $1,781 as compared with $1,600 in the prior year and $1,772 in the prior quarter. The year-over-year increase in revenue was primarily due to an increase in volume in primary care physicians and certified registered nurse anesthetists. The year-over-year increase in contribution income was driven by higher revenue, partially offset by higher direct costs.

Cash Flow and Balance Sheet Highlights

Cash flow provided by operations for the quarter was $18.1 million, primarily due to the strong net income growth, partly offset by an increase in accounts receivable. Days' sales outstanding, net of amounts owed to subcontractors, was 66 days as of June 30, 2022, up 10 days year-over-year and up 4 days sequentially, primarily due to the timing of revenue recognized throughout the quarter. For the six months ended June 30, 2022, cash flow used in operations was $10.9 million compared to $9.4 million in the prior year.

Given positive cash from operations, the Company made a $50.0 million optional prepayment on its Subordinated Term Loan to reduce interest costs. At June 30, 2022, the Company had $0.3 million in cash and cash equivalents and $123.9 million principal balance on its term loan, with $85.0 million of borrowings drawn under its ABL facility, and $17.5 million of letters of credit outstanding. As of June 30, 2022, borrowing base availability under the ABL was $300.0 million, with $197.5 million of excess availability.

Outlook for Third Quarter 2022

The guidance below applies to management’s expectations for the third quarter of 2022.

 

Q3 2022 Range

 

Year-over-Year

 

Sequential

Change

 

Change

 

 

 

 

 

 

Revenue

$605 million - $615 million

 

61% - 64%

 

(20)% - (18)%

 

 

 

 

 

 

Gross Profit Margin*

22.3% - 22.8%

 

(10) bps - 40 bps

 

(30) bps - 20 bps

 

 

 

 

 

 

Adjusted EBITDA*

$55.0 million - $60.0 million

 

83% - 99%

 

(34)% - (28)%

 

 

 

 

 

 

Adjusted EPS*

$0.85 - $0.95

 

$0.24 - $0.34

 

($0.55) - ($0.45)

* Refer to discussion of non-GAAP financial measures below.

The above estimates are based on current management expectations and, as such, are forward-looking and actual results may differ materially. The above ranges do not include the potential impact of any future divestitures, mergers, acquisitions, or other business combinations, changes in debt structure, or future significant share repurchases.

See accompanying non-GAAP financial measures and tables below.

INVITATION TO CONFERENCE CALL

The Company will hold its quarterly conference call on Wednesday, August 3, 2022, at 5:00 P.M. Eastern Time to discuss its second quarter 2022 financial results. This call will be webcast live and can be accessed at the Company’s website at ir.crosscountryhealthcare.com or by dialing 888-566-1290 from anywhere in the U.S. or by dialing 773-799-3776 from non-U.S. locations - Passcode: Cross Country. A replay of the webcast will be available from August 3rd through August 17th on the Company’s website and a replay of the conference call will be available by telephone by calling 800-814-6746 from anywhere in the U.S. or 203-369-3827 from non-U.S. locations - Passcode: 8322.

ABOUT CROSS COUNTRY HEALTHCARE

Cross Country Healthcare, Inc. is a leading tech-enabled workforce solutions and advisory firm with 36 years of industry experience and insight. We solve complex labor-related challenges for customers while providing high-quality outcomes and exceptional patient care. As a multi-year Best of Staffing® award winner, we are committed to an exceptionally high level of service to our clients and our homecare, education, and clinical and non-clinical healthcare professionals. Our locum tenens line of business, Cross Country Locums, has been certified by the National Committee for Quality Assurance (NCQA), the leader in healthcare accreditation, since 2001. We are the first publicly traded staffing firm to obtain The Joint Commission Certification, which we still hold with a Letter of Distinction. Cross Country Healthcare is rated as the top staffing and recruiting employer for women by InHerSights, and CertifiedTM by Great Place to Work®. For two consecutive years, we have received the Top Workplaces USA award and were recently recognized as a recipient of the Top Workplaces Award for Innovation and Leadership by Energage. We have a history of investing in diversity, equality, and inclusion as a key component of the organization’s overall corporate social responsibility program, closely aligned with its core values to create a better future for its people, communities, and its stockholders.

Copies of this and other news releases and additional information about the Company can be obtained online at ir.crosscountryhealthcare.com. Stockholders and prospective investors can also register to automatically receive the Company’s press releases, filings with the Securities and Exchange Commission (SEC), and other notices by e-mail.

NON-GAAP FINANCIAL MEASURES

This press release and the accompanying financial statement tables reference non-GAAP financial measures, such as gross profit margin, adjusted EBITDA, and adjusted EPS. Such non-GAAP financial measures are provided as additional information and should not be considered substitutes for, or superior to, financial measures calculated in accordance with U.S. GAAP. Such non-GAAP financial measures are provided for consistency and comparability to prior year results; furthermore, management believes they are useful to investors when evaluating the Company's performance as they exclude certain items that management believes are not indicative of the Company's future operating performance. Pro forma measures, if applicable, are adjusted to include the results of our acquisitions, and exclude the results of divestments, as if the transactions occurred in the beginning of the periods mentioned. Such non-GAAP financial measures may differ materially from the non-GAAP financial measures used by other companies. The financial statement tables that accompany this press release include a reconciliation of each non-GAAP financial measure to the most directly comparable U.S. GAAP financial measure and a more detailed discussion of each financial measure; as such, the financial statement tables should be read in conjunction with the presentation of these non-GAAP financial measures.

FORWARD LOOKING STATEMENTS

In addition to historical information, this press release contains statements relating to our future results (including certain projections and business trends) that are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the Private Securities Litigation Reform Act, and are subject to the "safe harbor" created by those sections. Forward-looking statements consist of statements that are predictive in nature, depend upon or refer to future events. Words such as "expects", "anticipates", "intends", "plans", "believes", "estimates", "suggests", "appears", "seeks", "will", "could", and variations of such words and similar expressions are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results and performance to be materially different from any future results or performance expressed or implied by these forward-looking statements. These factors include, but are not limited to, the following: the potential impacts of the COVID-19 pandemic on our business, financial condition, and results of operations, our ability to attract and retain qualified nurses, physicians and other healthcare personnel, costs and availability of short-term housing for our travel healthcare professionals, demand for the healthcare services we provide, both nationally and in the regions in which we operate, the functioning of our information systems, the effect of cyber security risks and cyber incidents on our business, the effect of existing or future government regulation and federal and state legislative and enforcement initiatives on our business, our clients’ ability to pay us for our services, our ability to successfully implement our acquisition and development strategies, including our ability to successfully integrate acquired businesses and realize synergies from such acquisitions, the effect of potential liabilities, losses, or other exposures in connection with the WSG acquisition, the effect of liabilities and other claims asserted against us, the effect of competition in the markets we serve, our ability to successfully defend the Company, its subsidiaries, and its officers and directors on the merits of any lawsuit or determine its potential liability, if any, and other factors, including, without limitation, the risk factors set forth in Item 1A. "Risk Factors" in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, and in our other filings with the SEC. You should consult any further disclosures the Company makes on related subjects in its filings with the SEC.

Although we believe that these statements are based upon reasonable assumptions, we cannot guarantee future results and readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management’s opinions only as of the date of this press release. There can be no assurance that (i) we have correctly measured or identified all of the factors affecting our business or the extent of these factors’ likely impact, (ii) the available information with respect to these factors on which such analysis is based is complete or accurate, (iii) such analysis is correct, and/or (iv) our strategy, which is based in part on this analysis, will be successful. Except as may be required by law, the Company undertakes no obligation to update or revise forward-looking statements. All references to "we", "us", "our", or "Cross Country" in this press release mean Cross Country Healthcare, Inc. and its subsidiaries.

Cross Country Healthcare, Inc.

Consolidated Statements of Operations

(Unaudited, amounts in thousands, except per share data)

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

 

Six Months Ended

 

June 30,

 

June 30,

 

March 31,

 

 

June 30,

 

June 30,

 

2022

 

2021

 

2022

 

 

2022

 

2021

 

 

 

 

 

 

 

Revenue from services

$

753,561

 

 

$

331,827

 

 

$

788,732

 

 

 

$

1,542,293

 

 

$

661,068

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

Direct operating expenses

 

583,156

 

 

 

259,237

 

 

 

613,938

 

 

 

 

1,197,094

 

 

 

517,013

 

Selling, general and administrative expenses

 

86,009

 

 

 

50,344

 

 

 

76,813

 

 

 

 

162,822

 

 

 

96,671

 

Bad debt expense

 

3,192

 

 

 

466

 

 

 

2,369

 

 

 

 

5,561

 

 

 

970

 

Depreciation and amortization

 

3,481

 

 

 

2,199

 

 

 

2,719

 

 

 

 

6,200

 

 

 

4,452

 

Acquisition and integration-related costs

 

—

 

 

 

924

 

 

 

40

 

 

 

 

40

 

 

 

924

 

Restructuring (benefits) costs

 

(1,114

)

 

 

835

 

 

 

480

 

 

 

 

(634

)

 

 

2,073

 

Impairment charges

 

—

 

 

 

1,921

 

 

 

1,741

 

 

 

 

1,741

 

 

 

2,070

 

Total operating expenses

 

674,724

 

 

 

315,926

 

 

 

698,100

 

 

 

 

1,372,824

 

 

 

624,173

 

Income from operations

 

78,837

 

 

 

15,901

 

 

 

90,632

 

 

 

 

169,469

 

 

 

36,895

 

Other expenses (income):

 

 

 

 

 

 

 

 

 

 

Interest expense

 

3,857

 

 

 

1,196

 

 

 

3,521

 

 

 

 

7,378

 

 

 

1,867

 

Loss on early extinguishment of debt

 

1,912

 

 

 

—

 

 

 

—

 

 

 

 

1,912

 

 

 

—

 

Other income, net

 

(1,084

)

 

 

(204

)

 

 

(8

)

 

 

 

(1,092

)

 

 

(241

)

Income before income taxes

 

74,152

 

 

 

14,909

 

 

 

87,119

 

 

 

 

161,271

 

 

 

35,269

 

Income tax expense

 

21,258

 

 

 

3,361

 

 

 

25,136

 

 

 

 

46,394

 

 

 

4,273

 

Net income attributable to common stockholders

$

52,894

 

 

$

11,548

 

 

$

61,983

 

 

 

$

114,877

 

 

$

30,996

 

 

 

 

 

 

 

 

 

 

 

 

Net income per share attributable to common stockholders - Basic

$

1.41

 

 

$

0.32

 

 

$

1.67

 

 

 

$

3.08

 

 

$

0.85

 

 

 

 

 

 

 

 

 

 

 

 

Net income per share attributable to common stockholders - Diluted

$

1.40

 

 

$

0.31

 

 

$

1.63

 

 

 

$

3.03

 

 

$

0.84

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average common shares outstanding:

 

 

 

 

 

 

 

 

 

 

Basic

 

37,471

 

 

 

36,625

 

 

 

37,028

 

 

 

 

37,251

 

 

 

36,404

 

Diluted

 

37,757

 

 

 

37,203

 

 

 

37,973

 

 

 

 

37,866

 

 

 

37,120

 

 

 

 

 

 

 

 

 

 

 

 

Cross Country Healthcare, Inc.

Reconciliation of Non-GAAP Financial Measures

(Unaudited, amounts in thousands, except per share data)

 

 

Three Months Ended

 

 

Six Months Ended

 

June 30,

 

 

June 30,

 

 

March 31,

 

 

June 30,

 


June 30,

 

2022

 

 

2021

 

 

2022

 

 

2022

 


2021

Adjusted EBITDA:a

 

 

 

 

 

 

 

 

 

 

 


 

Net income attributable to common stockholders

$

52,894

 

 

 

$

11,548

 

 

 

$

61,983

 

 

 

$

114,877

 

 


$

30,996

 

Interest expense

 

3,857

 

 

 

 

1,196

 

 

 

 

3,521

 

 

 

 

7,378

 

 


 

1,867

 

Income tax expenseb

 

21,258

 

 

 

 

3,361

 

 

 

 

25,136

 

 

 

 

46,394

 

 


 

4,273

 

Depreciation and amortization

 

3,481

 

 

 

 

2,199

 

 

 

 

2,719

 

 

 

 

6,200

 

 


 

4,452

 

Acquisition and integration-related costsc

 

—

 

 

 

 

924

 

 

 

 

40

 

 

 

 

40

 

 


 

924

 

Restructuring (benefits) costsd

 

(1,114

)

 

 

 

835

 

 

 

 

480

 

 

 

 

(634

)

 


 

2,073

 

Legal settlements and feese

 

—

 

 

 

 

28

 

 

 

 

—

 

 

 

 

—

 

 


 

403

 

Impairment chargesf

 

—

 

 

 

 

1,921

 

 

 

 

1,741

 

 

 

 

1,741

 

 


 

2,070

 

Loss on disposal of fixed assets

 

6

 

 

 

 

—

 

 

 

 

19

 

 

 

 

25

 

 


 

—

 

Loss on early extinguishment of debtg

 

1,912

 

 

 

 

—

 

 

 

 

—

 

 

 

 

1,912

 

 


 

—

 

Gain on lease terminationh

 

(1,064

)

 

 

 

(197

)

 

 

 

(21

)

 

 

 

(1,085

)

 


 

(224

)

Other income, net

 

(26

)

 

 

 

(7

)

 

 

 

(6

)

 

 

 

(32

)

 


 

(17

)

Equity compensation

 

2,114

 

 

 

 

2,137

 

 

 

 

1,601

 

 

 

 

3,715

 

 


 

3,486

 

Applicant tracking system costsi

 

172

 

 

 

 

315

 

 

 

 

195

 

 

 

 

367

 

 


 

690

 

Adjusted EBITDAa

$

83,490

 

 

 

$

24,260

 

 

 

$

97,408

 

 

 

$

180,898

 

 


$

50,993

 

Adjusted EBITDA margina

 

11.1

%

 

 

 

7.3

%

 

 

 

12.3

%

 

 

 

11.7

%

 


 

7.7

%

 

 

 

 

 

 

 

 

 

 

 

 


 

Adjusted EPS:j

 

 

 

 

 

 

 

 

 

 

 


 

Numerator:

 

 

 

 

 

 

 

 

 

 

 


 

Net income attributable to common stockholders

$

52,894

 

 

 

$

11,548

 

 

 

$

61,983

 

 

 

$

114,877

 

 


$

30,996

 

Non-GAAP adjustments - pretax:

 

 

 

 

 

 

 

 

 

 

 


 

Acquisition and integration-related costsc

 

—

 

 

 

 

924

 

 

 

 

40

 

 

 

 

40

 

 


 

924

 

Restructuring (benefits) costsd

 

(1,114

)

 

 

 

835

 

 

 

 

480

 

 

 

 

(634

)

 


 

2,073

 

Legal settlements and feese

 

—

 

 

 

 

28

 

 

 

 

—

 

 

 

 

—

 

 


 

403

 

Impairment chargesf

 

—

 

 

 

 

1,921

 

 

 

 

1,741

 

 

 

 

1,741

 

 


 

2,070

 

Applicant tracking system costsi

 

172

 

 

 

 

315

 

 

 

 

195

 

 

 

 

367

 

 


 

690

 

Loss on early extinguishment of debtg

 

1,912

 

 

 

 

—

 

 

 

 

—

 

 

 

 

1,912

 

 


 

—

 

Nonrecurring income tax adjustmentsk

 

—

 

 

 

 

1,942

 

 

 

 

—

 

 

 

 

—

 

 


 

1,942

 

Tax impact of non-GAAP adjustments

 

(1,061

)

 

 

 

(11

)

 

 

 

184

 

 

 

 

(878

)

 


 

(12

)

Adjusted net income attributable to common stockholders - non-GAAP

$

52,803

 

 

 

$

17,502

 

 

 

$

64,623

 

 

 

$

117,425

 

 


$

39,086

 

 

 

 

 

 

 

 

 

 

 

 

 


 

Denominator:

 

 

 

 

 

 

 

 

 

 

 


 

Weighted average common shares - basic, GAAP

 

37,471

 

 

 

 

36,625

 

 

 

 

37,028

 

 

 

 

37,251

 

 


 

36,404

 

Dilutive impact of share-based payments

 

286

 

 

 

 

578

 

 

 

 

945

 

 

 

 

615

 

 


 

716

 

Adjusted weighted average common shares - diluted, non-GAAP

 

37,757

 

 

 

 

37,203

 

 

 

 

37,973

 

 

 

 

37,866

 

 


 

37,120

 

 

 

 

 

 

 

 

 

 

 

 

 


 

Reconciliation:

 

 

 

 

 

 

 

 

 

 

 


 

Diluted EPS, GAAP

$

1.40

 

 

 

$

0.31

 

 

 

$

1.63

 

 

 

$

3.03

 

 


$

0.84

 

Non-GAAP adjustments - pretax:

 

 

 

 

 

 

 

 

 

 

 


 

Acquisition and integration-related costsc

 

—

 

 

 

 

0.03

 

 

 

 

—

 

 

 

 

—

 

 


 

0.03

 

Restructuring (benefits) costsd

 

(0.03

)

 

 

 

0.02

 

 

 

 

0.01

 

 

 

 

(0.02

)

 


 

0.05

 

Legal settlements and feese

 

—

 

 

 

 

—

 

 

 

 

—

 

 

 

 

—

 

 


 

0.01

 

Impairment chargesf

 

—

 

 

 

 

0.05

 

 

 

 

0.05

 

 

 

 

0.05

 

 


 

0.05

 

Applicant tracking system costsi

 

—

 

 

 

 

0.01

 

 

 

 

0.01

 

 

 

 

0.01

 

 


 

0.02

 

Loss on early extinguishment of debtg

 

0.05

 

 

 

 

—

 

 

 

 

—

 

 

 

 

0.05

 

 


 

—

 

Nonrecurring income tax adjustmentsk

 

—

 

 

 

 

0.05

 

 

 

 

—

 

 

 

 

—

 

 


 

0.05

 

Tax impact of non-GAAP adjustments

 

(0.02

)

 

 

 

—

 

 

 

 

—

 

 

 

 

(0.02

)

 


 

—

 

Adjusted EPS, non-GAAPj

$

1.40

 

 

 

$

0.47

 

 

 

$

1.70

 

 

 

$

3.10

 

 


$ 

1.05 

























 

Cross Country Healthcare, Inc.

Consolidated Balance Sheets

(Unaudited, amounts in thousands)

 

 


June 30,

 

 

December 31,

 


2022

 

 

2021

 


 

 

 

 

Assets


 

 

 

 

Current assets:


 

 

 

 

Cash and cash equivalents


$

279

 

 

 

$

1,036

 

Accounts receivable, net


 

701,926

 

 

 

 

493,910

 

Prepaid expenses


 

6,774

 

 

 

 

7,648

 

Insurance recovery receivable


 

5,750

 

 

 

 

5,041

 

Other current assets


 

3,594

 

 

 

 

638

 

Total current assets


 

718,323

 

 

 

 

508,273

 

Property and equipment, net


 

18,241

 

 

 

 

15,833

 

Operating lease right-of-use assets


 

5,058

 

 

 

 

7,488

 

Goodwill


 

113,360

 

 

 

 

119,490

 

Trade names, indefinite-lived


 

5,900

 

 

 

 

5,900

 

Other intangible assets, net


 

42,863

 

 

 

 

42,344

 

Non-current deferred tax assets


 

8,096

 

 

 

 

11,525

 

Other non-current assets


 

27,120

 

 

 

 

21,956

 

Total assets


$

938,961

 

 

 

$

732,809

 

 


 

 

 

 

Liabilities and Stockholders' Equity


 

 

 

 

Current liabilities:


 

 

 

 

Accounts payable and accrued expenses


$

189,805

 

 

 

$

109,753

 

Accrued compensation and benefits


 

65,409

 

 

 

 

65,580

 

Current portion of debt


 

—

 

 

 

 

4,176

 

Operating lease liabilities - current


 

4,145

 

 

 

 

4,090

 

Income tax payable


 

30

 

 

 

 

7,307

 

Current portion of earnout liability


 

7,500

 

 

 

 

7,500

 

Other current liabilities


 

1,769

 

 

 

 

1,364

 

Total current liabilities


 

268,658

 

 

 

 

199,770

 

Long-term debt, less current portion


 

205,376

 

 

 

 

176,366

 

Operating lease liabilities - non-current


 

7,017

 

 

 

 

10,853

 

Non-current deferred tax liabilities


 

222

 

 

 

 

190

 

Long-term accrued claims


 

26,869

 

 

 

 

25,314

 

Non-current earnout liability


 

7,500

 

 

 

 

9,000

 

Other long-term liabilities


 

12,508

 

 

 

 

13,788

 

Total liabilities


 

528,150

 

 

 

 

435,281

 

 


 

 

 

 

Commitments and contingencies


 

 

 

 

 


 

 

 

 

Stockholders' equity:


 

 

 

 

Common stock


 

4

 

 

 

 

4

 

Additional paid-in capital


 

320,000

 

 

 

 

321,552

 

Accumulated other comprehensive loss


 

(1,335

)

 

 

 

(1,293

)

Retained earnings (accumulated deficit)


 

92,142

 

 

 

 

(22,735

)

Total stockholders' equity


 

410,811

 

 

 

 

297,528

 

Total liabilities and stockholders' equity


$

938,961

 

 

 

$ 

732,809 







 

Cross Country Healthcare, Inc.

Segment Datal

(Unaudited, amounts in thousands)

 

 

Three Months Ended

 

Year-over-Year

 

Sequential

 

June 30,

 

% of

 

June 30,

 

% of

 

March 31,

 

% of

 

% change

 

% change

 

2022

 

Total

 

2021

 

Total

 

2022

 

Total

 

Fav (Unfav)

 

Fav (Unfav)

 

 


 

 

 


 

 

 


 

 

 

 

 

Revenue from services:

 


 

 

 


 

 

 


 

 

 

 

 

Nurse and Allied Staffing

$

731,443

 


97

%

 

$

316,188


95

%

 

$

765,580


97

%

 

131

%

 

(4

)%

Physician Staffing

 

22,118

 


3

%

 

 

15,639


5

%

 

 

23,152


3

%

 

41

%

 

(4

)%

 

$

753,561

 


100

%

 

$

331,827


100

%

 

$

788,732


100

%

 

127

%

 

(4

)%

 

 


 

 

 


 

 

 


 

 

 

 

 

Contribution income:m

 


 

 

 


 

 

 


 

 

 

 

 

Nurse and Allied Staffing

$

97,567

 


 

 

$

35,284


 

 

$

110,101


 

 

177

%

 

(11

)%

Physician Staffing

 

1,220

 


 

 

 

562


 

 

 

1,765


 

 

117

%

 

(31

)%

 

 

98,787

 


 

 

 

35,846


 

 

 

111,866


 

 

176

%

 

(12

)%

 

 


 

 

 


 

 

 


 

 

 

 

 

 

 


 

 

 


 

 

 


 

 

 

 

 

Corporate overheadn

 

17,583

 


 

 

 

14,066


 

 

 

16,254


 

 

(25

)%

 

(8

)%

Depreciation and amortization

 

3,481

 


 

 

 

2,199


 

 

 

2,719


 

 

(58

)%

 

(28

)%

Acquisition and integration-related costsc

 

—

 


 

 

 

924


 

 

 

40


 

 

100

%

 

100

%

Restructuring (benefits) costsd

 

(1,114

)


 

 

 

835


 

 

 

480


 

 

233

%

 

332

%

Impairment chargesf

 

—

 


 

 

 

1,921


 

 

 

1,741


 

 

100

%

 

100

%

Income from operations

$

78,837

 


 

 

$

15,901


 

 

$

90,632


 

 

396

%

 

(13

)%

 

 


 

 

 


 

 

 


 

 

 

 

 

 

 


 

 

 


 

 

 


 

 

 

 

 

 

Six Months Ended

 

 

 

Year-over-Year

 

 

 

June 30,

 

% of

 

June 30,

 

% of

 

 

 

% change

 

 

 

2022

 

Total

 

2021

 

Total

 

 

Fav (Unfav)

 

 

 

 


 

 

 


 

 

 


 

 

 

 

 

Revenue from services:

 


 

 

 


 

 

 


 

 

 

 

 

Nurse and Allied Staffing

$

1,497,023

 


97

%

 

$

629,196


95

%

 

 


 

 

138

%

 

 

Physician Staffing

 

45,270

 


3

%

 

 

31,872


5

%

 

 


 

 

42

%

 

 

 

$

1,542,293

 


100

%

 

$

661,068


100

%

 

 


 

 

133

%

 

 

 

 


 

 

 


 

 

 


 

 

 

 

 

Contribution income:m

 


 

 

 


 

 

 


 

 

 

 

 

Nurse and Allied Staffing

$

207,668

 


 

 

$

72,701


 

 

 


 

 

186

%

 

 

Physician Staffing

 

2,985

 


 

 

 

1,990


 

 

 


 

 

50

%

 

 

 

 

210,653

 


 

 

 

74,691


 

 

 


 

 

182

%

 

 

 

 


 

 

 


 

 

 


 

 

 

 

 

 

 


 

 

 


 

 

 


 

 

 

 

 

Corporate overheadn

 

33,837

 


 

 

 

28,277


 

 

 


 

 

(20

)%

 

 

Depreciation and amortization

 

6,200

 


 

 

 

4,452


 

 

 


 

 

(39

)%

 

 

Acquisition and integration-related costsc

 

40

 


 

 

 

924


 

 

 


 

 

96

%

 

 

Restructuring (benefits) costsd

 

(634

)


 

 

 

2,073


 

 

 


 

 

131

%

 

 

Impairment chargesf

 

1,741

 


 

 

 

2,070


 

 

 


 

 

16

%

 

 

Income from operations

$

169,469

 


 

 

$

36,895


 

 

 


 

 

359

%

 

 




















 

Cross Country Healthcare, Inc.

Summary Condensed Consolidated Statements of Cash Flows

(Unaudited, amounts in thousands)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

 

Six Months Ended

 

June 30,

 

 

June 30,

 

 

March 31,

 

 

June 30,

 

June 30,

 

2022

 

 

2021

 

 

2022

 

 

2022

 

2021

 

 

 

 

 

 

 

 

 

 

 

 

 

Net cash provided by (used in) operating activities

$

18,141

 

 

 

$

15,505

 

 

 

$

(29,038

)

 

 

$

(10,897

)

 

$

(9,422

)

Net cash used in investing activities

 

(1,752

)

 

 

 

(26,286

)

 

 

 

(2,096

)

 

 

 

(3,848

)

 

 

(27,472

)

Net cash (used in) provided by financing activities

 

(17,321

)

 

 

 

15,434

 

 

 

 

31,308

 

 

 

 

13,987

 

 

 

53,438

 

Effect of exchange rate changes on cash

 

3

 

 

 

 

(14

)

 

 

 

(2

)

 

 

 

1

 

 

 

(17

)

Change in cash and cash equivalents

 

(929

)

 

 

 

4,639

 

 

 

 

172

 

 

 

 

(757

)

 

 

16,527

 

Cash and cash equivalents at beginning of period

 

1,208

 

 

 

 

13,488

 

 

 

 

1,036

 

 

 

 

1,036

 

 

 

1,600

 

Cash and cash equivalents at end of period

$

279

 

 

 

$

18,127

 

 

 

$

1,208

 

 

 

$

279

 

 

$

18,127

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cross Country Healthcare, Inc.

Other Financial Data

(Unaudited)

 

 

Three Months Ended

 

 

Six Months Ended

 

June 30,

 

 

June 30,

 

 

March 31,

 

 

June 30,

 

June 30,

 

2022

 

 

2021

 

 

2022

 

 

2022

 

2021

 

 

 

 

 

 

 

 

 

 

 

 

 

Consolidated gross profit margino

 

22.6

%

 

 

 

21.9

%

 

 

 

22.2

%

 

 

 

22.4

%

 

 

21.8

%

 

 

 

 

 

 

 

 

 

 

 

 

 

Nurse and Allied Staffing statistical data:

 

 

 

 

 

 

 

 

 

 

 

 

FTEsp

 

13,494

 

 

 

 

7,578

 

 

 

 

13,454

 

 

 

 

13,474

 

 

 

7,096

 

Average Nurse and Allied Staffing revenue per FTE per dayq

$

591

 

 

 

$

454

 

 

 

$

628

 

 

 

$

609

 

 

$

486

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Physician Staffing statistical data:

 

 

 

 

 

 

 

 

 

 

 

 

Days filledr

 

12,416

 

 

 

 

9,775

 

 

 

 

13,068

 

 

 

 

25,484

 

 

 

19,244

 

Revenue per day filleds

$

1,781

 

 

 

$

1,600

 

 

 

$

1,772

 

 

 

$

1,776

 

 

$

1,656

 

(a)


Adjusted EBITDA, a non-GAAP financial measure, is defined as net income (loss) attributable to common stockholders before interest expense, income tax expense (benefit), depreciation and amortization, acquisition and integration-related costs, restructuring (benefits) costs, legal settlements and fees, impairment charges, gain or loss on derivative, loss on early extinguishment of debt, gain or loss on disposal of fixed assets, gain or loss on lease termination, gain or loss on sale of business, other expense (income), net, equity compensation, and applicant tracking system costs. Adjusted EBITDA should not be considered a measure of financial performance under GAAP. Management presents Adjusted EBITDA because it believes that Adjusted EBITDA is a useful supplement to net income attributable to common stockholders as an indicator of operating performance. Management uses Adjusted EBITDA for planning purposes and as one performance measure in its incentive programs for certain members of its management team. Adjusted EBITDA, as defined, closely matches the operating measure as defined by the Company's credit facilities. Adjusted EBITDA Margin is calculated by dividing Adjusted EBITDA by the Company's consolidated revenue.

(b)


The Company released the majority of its valuation allowance on deferred tax assets as of December 31, 2021, resulting in increased income tax expense in 2022.

(c)


Acquisition and integration-related costs include costs for legal and advisory fees for the Workforce Solutions Group (WSG) acquisition that closed on June 8, 2021.

(d)


Restructuring (benefits) costs are primarily comprised of employee termination costs, lease-related exit costs, and reorganization costs as part of planned cost savings initiatives. Amounts for the three and six months ended June 30, 2022 include a benefit associated with the early termination of one of the Company's corporate offices which was previously restructured.

(e)


Legal settlements and fees include legal settlement charges as presented on the consolidated statements of operations as well as legal fees pertaining to non-operational legal matters outside the normal course of operations which are included in selling, general and administrative expenses. For the three and six months ended June 30, 2021, we incurred legal fees related to various legal matters outside the normal course of operations.

(f)


Impairment charges for the six months ended June 30, 2022 was comprised of $1.7 million related to right-of-use assets and related property in connection with leases that were vacated. Impairment charges for the six months ended June 30, 2021 was comprised of $1.9 million related to right-of-use assets and related property in connection with leases that were vacated during the second quarter and $0.1 million related to the write-off of a discontinued software development project.

(g)


Loss on early extinguishment of debt for the three and six months ended June 30, 2022 consists of a prepayment premium and the write-off of debt issuance costs related to the optional prepayment on our term loan made in the second quarter of 2022.

(h)


The gain on lease termination for the three and six months ended June 20, 2022 is a result of the early termination of one of the Company's corporate offices, recognized in the second quarter of 2022.

(i)


Applicant tracking system costs are related to the Company's project to replace its legacy system supporting its travel nurse staffing business. These costs are reported in selling, general and administrative expenses on the consolidated statement of operations and included in corporate overhead in segment data.

(j)


Adjusted EPS, a non-GAAP financial measure, is defined as net income (loss) attributable to common stockholders per diluted share before the diluted EPS impact of acquisition and integration-related costs, restructuring (benefits) costs, legal settlements and fees, impairment charges, gain or loss on derivative, loss on early extinguishment of debt, gain or loss on sale of business, applicant tracking system costs, and nonrecurring income tax adjustments. Adjusted EPS should not be considered a measure of financial performance under GAAP. Management presents Adjusted EPS because it believes that Adjusted EPS is a useful supplement to its reported EPS as an indicator of operating performance. Management believes it provides a more useful comparison of the Company's underlying business performance from period to period and is more representative of the future earnings capacity of the Company.

(k)


Non-recurring income tax adjustment for the three and six months ended June 30, 2021 reflects a valuation allowance related to a state rate change as a result of the WSG acquisition.

(l)


Segment data provided is in accordance with the Segment Reporting Topic of the FASB ASC.

(m)


Contribution income is defined as income (loss) from operations before depreciation and amortization, acquisition and integration-related costs, restructuring (benefits) costs, legal settlement charges, impairment charges, and corporate overhead. Contribution income is a financial measure used by management when assessing segment performance.

(n)


Corporate overhead includes unallocated executive leadership and other centralized corporate functional support costs such as finance, IT, legal, human resources, and marketing, as well as public company expenses and corporate-wide projects (initiatives).

(o)


Gross profit is defined as revenue from services less direct operating expenses. The Company's gross profit excludes allocated depreciation and amortization expense. Gross profit margin is calculated by dividing gross profit by revenue from services.

(p)


FTEs represent the average number of Nurse and Allied Staffing contract personnel on a full-time equivalent basis.

(q)


Average revenue per FTE per day is calculated by dividing Nurse and Allied Staffing revenue, excluding permanent placement, per FTE by the number of days worked in the respective periods.

(r)


Days filled is calculated by dividing the total hours invoiced during the period, including an estimate for the impact of accrued revenue, by 8 hours.

(s)


Revenue per day filled is calculated by dividing revenue as reported by days filled for the period presented.

 

Contacts

Cross Country Healthcare, Inc.
William J. Burns, Executive Vice President & Chief Financial Officer
561-237-2555
wburns@crosscountry.com

EX-101.SCH 3 ccrn-20220803.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 ccrn-20220803_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Amendment Flag Document Fiscal Year Focus Document Fiscal Period Focus Document Period End Date Entity Registrant Name Entity Central Index Key Entity File Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Emerging Growth Company Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name EX-101.PRE 5 ccrn-20220803_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 cc_logo.jpg begin 644 cc_logo.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.2
Document and Entity Information
Aug. 03, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 03, 2022
Entity Registrant Name Cross Country Healthcare, Inc.
Entity Incorporation, State or Country Code DE
Entity File Number 0-33169
Entity Tax Identification Number 13-4066229
Entity Address, Address Line One 6551 Park of Commerce Boulevard
Entity Address, Address Line Two N.W.
Entity Address, City or Town Boca Raton
Entity Address, State or Province FL
Entity Address, Postal Zip Code 33487
City Area Code 561
Local Phone Number 998-2232
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Entity Central Index Key 0001141103
Title of 12(b) Security Common stock, par value $0.0001 per share
Trading Symbol CCRN
Security Exchange Name NASDAQ
XML 8 a52798979_htm.xml IDEA: XBRL DOCUMENT 0001141103 2022-08-03 2022-08-03 false 0001141103 8-K 2022-08-03 Cross Country Healthcare, Inc. DE 0-33169 13-4066229 6551 Park of Commerce Boulevard N.W. Boca Raton FL 33487 561 998-2232 Common stock, par value $0.0001 per share CCRN NASDAQ false false false false false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2 html 1 23 1 false 0 0 false 0 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://crosscountryhealthcare.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports a52798979.htm a52798979ex991.htm ccrn-20220803.xsd ccrn-20220803_lab.xml ccrn-20220803_pre.xml cc_logo.jpg http://xbrl.sec.gov/dei/2021 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "a52798979.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "a52798979.htm" ] }, "labelLink": { "local": [ "ccrn-20220803_lab.xml" ] }, "presentationLink": { "local": [ "ccrn-20220803_pre.xml" ] }, "schema": { "local": [ "ccrn-20220803.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2004/ref-2004-08-10.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" ] } }, "elementCount": 29, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "ccrn", "nsuri": "http://crosscountryhealthcare.com/20220803", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "a52798979.htm", "contextRef": "c20220803to20220803", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000100 - Document - Document and Entity Information", "role": "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "a52798979.htm", "contextRef": "c20220803to20220803", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 15 0001157523-22-001011-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001157523-22-001011-xbrl.zip M4$L#!!0 ( .2# U6,(0I5/A( -=G - 834R-SDX.3T] M:W/:2+;?M^K^A[[,WEF[RH#>#_RH>":Q7=AS,[M?MEK=+=!&2$Q+Q'!_ M_3W=DD" -G&B9.QRQ4C^G7>K^Y63H;I*$3341@EG:G'P^"T,4S3<:?=?GAX M:(EO6C$?M#5%T=M!E*0X(JR1]P^#Z/.6[J+9P\F\^W2M_X,N>ZNNZ[9EZ[QK M$E1UA&G5]A\?/]R1(1OAYBH\8GFZ&%B&QFIGC477((D-3;6W(9OUF ^8;NJK M"L( \.R/=_T/B^YI=?]%UW;*<93X,1_A-(@C,9/95+2F9I4F:2:,+$T$SZU! M_&7G/$Y35XMY)DES@/%X/H^/$T\"DS? $$UM*FII"&4K="S6A0;9?3YWRC<2 MT6U#:]&1Q),HY;/J6?/&I9G)A',6D4TC\M:E(1$.2%+=7S8M=4X"4MT5&I8[ MIF.^H2>T+'5E4S*L[BI:EF?EZ3I#X,LJ9J2\F<[&+*FF-#2W1;,8J8B1)1H2 M'LT'$1XG24[I(<-A.B28LQ:)1V*DICB*GH_;K*3"6C3._NMO")W %%1^@L]I MD(;L[*2=__[ L=C3'E !PPUFP5$(Y9B)%!KLC\GP9?31C>.4EBX>0_D:R"2/9TV4C9-VQ)5 MU(:Q)^T<5_CHQ72&DG06LM.&#_V;/AX%X:R#_G$?C%B"KMD#ZL. ?(]D["?Z/=9"JC--C)%9IXC 81!T4,A^^(7$8\P[Z29$_Q\C#Y/. M \=HLVCRY<^QX,$)#;Z@@)XV+NYN+P-A"MX'E+*H4"2&LJ!S#CRA@B^7(1XTY$J7F*3_MBVFFS[V M%,?2#-]G'E-LG1#=,BQ#LPPE)^0T[3/_M$$*V4KCA91EUNJT 1:NX\5QR'#D MXQ!@FDSB+T()&[6!1@Y#J\BRJ:_L5D)5$O#OF%@6[%MS? TZA'5 M=TU;51T&2!"R&]0S8(2J&JJJZ&M0M9>)R)G/A$UBR=F)<&:=1+HIF!I)Y]89 M94:I=4H WZ(Y4:+$/V41H)\?'$ MXU+SY1>E?EESH5]E!08SES)^W#@K+%.YXPY#D=F)"C.A@9D EB5C'"U-E3=; MPHK(+QZ8,( =Y,4AA1&_7U_=]R[0W?WY?>_NI"W&;Y^E"%4YI*4X90O<:[H<9+2 NZEI;\PG@8$AX4$>W&:QJ,Y2-EC!VGC*4KB M,*"KD!2$3.G9&BCM)5B*3\*32CJ?U>'('O1GHX)I8A'LJA@[DP( M(8;J:H2Y.C-\G3H:_&&8&:ZM6.YZWK7*[80G$PR1=QJC.T9$_I@AJNHHYD@U#^@ABGV4#IEH MG_ @#0"M'B0S.(+0^IRDHEEU=>.)( HG+J;HLW',4W10/#,,;IPE*6)?1&; M93,#:'9J[:V,!'I9?%!27T>S;$LEAN_XFJ$IU"78\#W/L#W=<'6;/3)LI3#[ M" 8,*9[- %J(N\_.)X,)@*P?R1SD,9H>C 8HX41$A_\.XT'<^L\80F[(T4X; M X['PX"(5&0>BY3B%90[OOFL19AL;(L(EO5[S@8U=&52?#8)$ MU)'2:V@I*8VF&:[#(%5R'6QXO@ZZXWK8U73'-BU%JY'KG75%V0&R=%EW0._G MA8(OS1E=:[EN!6_2>+RTPKH%&F$^"*(FS^R&6ATIH\H4 M=X?E.K4TG] VDW1 YR [D'1[]"ZI'00&8H55@^;14($):,U>%K,@#5=.G& MHU&0)'LE@[ 1*)/?9U/@Y27CJM5OW;50;S0.XQGC^R/#LCZCZ[A5CQK?O)A0 M"HZW5Z=13@K@1@; M2PF; -;* 'N>K7N.83"J&JII8NK;V&!$5UUJJ9I= ^#KUJ>U_*,/O MXX>H!!-6J64Z+OAQ@QF^ZWF:XFG$P00<#B.T#DSO8H)1'Z?"OCP-,FFY;_@M M1&&!/)RQV#BDX/H(2S&&*$]WP!<2QS-IC0+J[H#O$B+M@.)5X&O" M?AO#A.&_@O%*J&I3S;!,C6)@NF&88J.98GC4L0I_[#H!DZX;CKVK)+1;@Y^H ML& W8IM6J[C@?&@N(84 MF9:Z*D-;2J(?0)G#VV$=\2:%>%*Y^_LG15/LX =\>LK' &442Z2,$PAY.1.*/(!/$@-@/)MPY MA$O;MKNVJ7=N#5S'*3H?CT,(AR!^R6%L[Z7E>,>4>K;=5QK M]7!6N?C76$L(EI_64^LM*93>TD4265-MG\&^>W%:+]ML(T-$0,>2N32N97RO M >"=1NN>8VGG[V8C^&:.S&O&Z3K?J9 \8,7&*JC,PS" ;Q9ZM1F-RHK.O@5O M4XR1VX 91/%2GLH')B R5CQ3]W6&#01H7"UK' MY/,1&F..ON!PPM#?E98XB8;&XLC:\!$%WKW)P"9ZY"*826 Y7S0M'[(S17=\ MSP!<,=%=FYBNIRB&Y6*U#C&Z_>M7@V?!]^(LP,K&H4!44RA15,L0)R]=U="( MCDT'HE[+=VN@NY;K">4HTKQ[<"/7.*'X3W0G9 -]A+R?I>C#A^Z3*;2Q,%I\ M6JOEU/3(102Y LA^_7/%@MTA \H(CXO'D"./>2!JJEX\11X+XP<198E&$8LA MI_D;RLY:HR"!B#EE$97'MB$ &TW"%$B.RB6='FQR$L+L:)O#T0I]I&F*RWHN&V/_BE,OXLAM8'5HL%'T I0C;*Q MIN"??,?Q/)_JANS=>6[P32 J!$)G3>. U!.(O._6(UL[#@CM+\*Z MBJA "X*J&2(RVAJ)_:>'(9.[UBNA$ 160%*@B=B$&Z !CQ_2H:#.6(1'.$&4 M^4&4G4[+_*-B5IR^71RZU=&!8)I]+'VD8AZ*6EI&4LUK:NMC%\%GU1'>^6R" MSF*"P]9+T$YNQ +Q>AL(L6.KIACVBQS5S0:5]15;CF+JV& V-33%]C0LMA!5 M2Q7GBKP:6>>3]77?0>QSI=/?(F^B+%XIO,%:"#\$T60A(^)J9A1+O9TD3/:" M1?-$05Q"#F0.D%W%$D24:X4SL?A# $L+[D8 /[1P!J$_C .!QQ&!<&$AFIC( M2ZIBE+C?33&G298KT$W51?T SZN+9;R:.-P>;<\ MJP'FWQ1'';-=B*QREEW#O,4#]HXS_%EL_U1?!AM#EZ8G^C2Q#Z%2!^'P <^2 M#1,M;>\/>3%+?MHP3^&E/ZB O8.,\31K73JK.,QK4)HH\M"8M%5-+]U_W0M?EHVNQ_DKE(V M0EI+T;:'!'V63,)4[AS?@'+G;APTLT2+;@S6Y+N@1.,,C$49O9L(912WZC'A^#I(9ZD"(/9$EON'*PG!HN)HPAF$UL6 M\%5&4V$EQ0Q_3N1)=)19TU\G$Q>SF6I92L/!R47#I.4PQVG(I( MHC<=!EZ08^2Z+568RW0($4A7OC@A+2[<@&@7]9\6NA_*VL]!R*F SP7%!$SA@'V@A#B!C%',@&:)=FJ MSXAM'K<'4%'ZF^\J?GV=+VANSPU:GPTF8<;ORXM7K[Z;#9G=4M1=AJR$*;H( M$A+&R41L'KQRI$6F49Q3!=V"@&W^(@"95:S8F=S\>%F5-C=.0M4K[5QA218& M!'2*@;U8V!$D3$@K&U?;2"S$?5V@M7M)(?#-]*$CE5D0M\GR>R,LS%YYS M./D^$962Y>Y4_.\?>XA:Z&$MQ%MK+%:N]'\&H>]]JYYMU]G/YRFC95:?] MBWMQM>6F]NEZMZ79&P[7[UYMVQ'Y#3*SIGW;YL]E\YD7"!RSY6ZZ0O'M<;Q@ M">'!>-,ME)>X:_-:A.SE%MS$\N>N^ ,1_W5(_PE&V2NLL*G9KN/:+INZKMH: MIB-Q&KBEGK3QV0^M_ULI<"MC\/Z.&'P51/&S^MZ(FE1\$_ ]LU=5C!]:?+LQ MP(5$:1E=B?-=F,BK'Q CQ@(X]148$2]?H@DK)[)5\UBL0+!A'-7[*R M]YMQ7Z&0_%;;?W9M?U>^4>]"1]TD]NJ7Z_/[W_OB%7:O/CLKOTDIVS[[][O':&KZV[K MJP547S=WLK[J:B^"W!O1WXC^1*)_C:BZ.X-XMRCM;#Q# MNUK062?J(KW:2NK7+\8OSJS%*RK^-R ,B2J;?.4\^AF/8/WN,&!^:7LS>X]% MY6N!OFE]HICF\:?=-KV,?O'YI"W^6XHS^3]5I*,0/OP_4$L#!!0 ( .2# M U5/'QT)MW4 ,P<#P 2 834R-SDX.3=^)TMMK!U9\DAR$N;3W]TM M&PP8@L&6JEO_.6?M@)$E5775KZNK^F%_G$^B-__O_\/8_IA[@?I)_)R'><3? M[+\L_IU_^'\:#?8I]'F<\8#ER2OV=I:%,<\R]E>8\N(B]=^[Q)]->)PS/^5> M+BZ6UUVPPWC,!(_9^S+Z8GXD;/>7FNON==<^O9!,KU,PXMQSNQ^O\T: MS&DZ#GN;)EZ0AL$%9XU&\<(OYV^\/TR"2S:\\),H27_?^66D_MMA67X9\=]W M1DF<-T;>)(PN7['_.@\G/&/'_#L[329>_%\64Y]8+.-I.'K-U-59^ ]_Q>SF M-'_-!&_8A$?B4_4_HB01U^S+&]]X MI>]<_ND5&R91("XX_#$.AV'.^OT]>_^EO.+-_C"=2RINOIFGL,4]Y5V+A_ST MYDKJ1]V[N./\]O)N?N1EV>\[P^^-E$?8\ M?F"99F(>)^&,89V' 7[\_.3YOG!W]?X>BI5O3O%#.FX,T$09] MD,SB/+UD'[D7Y6/?2SD;Q+'XT!?&<\;]) [8?\^\5#RD,,_W8>S%?NA%[)1G MLRC/]E\.I4+&]LW772E20QKP3;GNO33WAD*8_V1LZ;,L3]([WQ=WF+YY>W(P M8*>#\Y-CB[V/O+U&8_?MGV='QX=G9^ROH]/#%XW&8'8QRW+F6DJ01N,^!5CL M*/;WV&X^YFSG()E,O?ARYP7;/?:RP/O[%3LX.#U^(; 0>)?,F^LJ8*,KO:2% M7H2#I2P4_V:%%O^>:Y''@;C\W[.8,[=9O,N>T-]TE52RGG!^^8^^/ MC@?'!T>#3^SH^/W)Z>?!^=')\:NY^E=\72E0&$@495//%RSZ?:>YP\+@]YU_ MNO:PSYU1T_$"WO(Z[9[=ZWK#SJCKNP&W@^X54B9>>A'&HMGR/)DH4/QX/?], M.LLK)C]@\T_2PDF\69Z\_AX&^5A^H?G;7=3<;4'&[GXB14A77%G\)9!T$H+% MO^_8.RQ-OE_]/'_U;SS-0]^+%IY2R/!ZF*0!3QMY,GW%LB0* S:,//\KL\5[ MS?]62';GC^*'BU2T=M!8<-'W.1^-7D^](!#J7=+(7/J.\]M*61?M>X^6EW6J MWE-^()SV7[_8G>;KE8T]O^/+/'A 81M2TAIZ6)=4.]>-ZFQ*<6N_P_,5_1/+ M?)IV%QXE3:IXP>>]!;&F7Q;/V(:_5W\/:?V)FFP]3I/KWAVLNLNJ5H6*%A'" M_WAI*&(/?F\H -O5T7:+O\V#*ECV4]I#_&%U!+G%R!+1(R+$[<&VK"@0D=Z6 M&A ](@5V5-RO_;=3)-.^917%;+#"QW3EM8Z]GF^CVXF^YFVSD$"S'-Z[)(J\ M-&,RT1[&+!\GL\R+@\QB_(?/ISF;\I1E8_EG;R)3T]E&[?UGRJN395<[7+ZO M"4!F6.HM2[5AJ3I;*F*)-_]M/XNX=-(X984)I_P;CV=\:TY_C^QWQ5M\,C?? M)8D?.7Z_.WEC$S;U*V7-]*O43+?M6NV.O37]E)2 NM?1-I@VVGX::+G+NYZ/ MM-EGZ.[*6VZ"#:BG4Z5Z;*>KC2\_2JFW&T0(>R.R49/PMILCGL_S8[_!\>'X M5!U_MT59-5OVS!?;GGQUSW#,0%Y1'CRM&/T&KOR_+0VK/J@IO],T&87Y_.__ MEZ27_50Q(/<3%5?IX,QQ]CI;4]N3YVH_SMBV$R#>_VP#45QQ,Y*-1D&[;2FN MT@BVV]302<"Z.ZP;3I]1A ;M0+M:T*ZU/=I1L+:GPF/+]K0%?NB<(7@BJBGG M"+:3"3CFN?!O/YEPYN5Y&@YGQ7+9/!%2329)+.Z7^%_'223>=7O=G^XY7-1A M[]-,V[%Z_>VE<)^],!OUVQ*T3#8&I< .PI$FA7C2;??(VC4JQN2:!*@!:IY< M:K;;E'6C;:WYZ8-3C8>@*%(_1Z-RB5 8S>1>W\)VRM+VW MQ>2E!J6:1[=LFELM[GGN'KJ MK89C\B<6C)<5]@2L4!X9;V?\.PC^,\O4 /CMT?F[ )KS[5:?8)# M6A1?2]0RV4". CM0$7EXH4:K!E,W4'P%:AA04_4@T,9"7U(^C>+KM98K'V*6 M77R]-?C$(F$3L4^\&FOO;6_[)@TJ&N8LG",8L*+\ =J1JH&X/8)Y.L .JX0W M\-K '47%53S:=[!.6)=$ )8(W_@#V23!ME,!7\YH)@ H] 0H0M\[CB_WM30L$.4 .D,-0[E/<7:BOE@K:;T4HI>JUU(O+USEO0GZP812KLZ M0G'*#C ,#-<'PQW'2*76=9OMI\)+YQ)[F;/PEQOKNA';#TPPV^#(Y?^R4S[B MJ=PUV_/]9"(>?BD>QM1>VAGSXH %8>;/LDR0@"4C%B=QX\-@\(7M?N Q3[TH MNF0#W^=366<7/PA+R.4-OJ1A[(=3<9,7;!3&GOC%B]B$>]DL%3<>\BCYOK=! M+=_^1%PF1;ASY?Y4G6=]QOU$R/;?,R_-A?AO9UD8\RQC'X4Y1M(DLWN/NMZ? M10LE+]$ROYSR5TI7*YMG/PJOSX266KV]3('_\#D/Q.\7LS 0VN(L]>(++O-: MXJOWWM 73L;BV60HA!"M(P]&XZJMO"ACHL4\\/?W?"S,0QV])AI<=!)"5_)QPX7:'KKWZ@49\NMRGOQO M#W[WDS>+_;'X[E&<\R@*1Y<62V:IE'.:ACSWTDOV/SP.DI1]]F+O@BM)SR[% M\R9L=/5IP,YX^BT42OV2)A>I-\G8[N>S+]F+A[4;9EPF&0,^D2V6CP7F+L;) M+!<_-QXM*?YA[?S:;NXUV204PDD'F^:J[82 M?.I=*FG$Q_)YXED3%B5>O/IV^R]GT4IC_]"K$FRB3SL9>S;)Q\][U,6H"XI[@D MD?Z>S00$A"4(?47"S%/O0F&$^^-8= L7E\KHY1<"SJ?B:5&1MAV'TTS"AX]& MH1\*<846IZ*3X+=,>6Y]4A%C[D7YV/=2OGC9V62/_27<*N5WE2PL(E6O,DJ3 MB?J^0)QHT= 73<0\-A(]ER?UK!HP"$>"AE+K(J&AAFP\2WPKRSWA,,%C?,I2#6>_9IDG.LY_ M)^-8&+/H(./,$E;,940F7E-J]6 <\A$[_,']62Y>[JX.3J1R"T 2$H+ MU_EXI!^)^5]%]Z MT)?!A\/&V]/#P1^-P?OS0W%[+Q+29"MNM[J?WQ^GBWN]/3E]=WC:^'3X_KSQ MU]&[\X_SCO[CX=&'C^>OF"-_F5]T*C^Z<=7\9[O9_.WJJD+^&Y<=G'PZ$6_Y M2U/]MU(I8H@Z_5%PFQL0ORBP\:9SIO(O]+IS[UV[;W>LLV"IM41X8(A2;*=>UG>YOM_LZ:8"> M,-#KJUJ_"0O\>R9,42%^3_C.TN,N[AY'JAXMCXG\S9(VVVVRH9>%XB*!26'. M*QXHKFK=O.INL]]\AS7//E'*:#M[_:M^1M$M+9SY5]$-MZ_^$A:]C>A=A7== MO>*O'6>IE[IQS;P9]JYVO17?B87#9K+G$)V%Y/3NX9>S%\5KJ#EU-Q[?W'/M M&[>\*_WU>]A['?>>YU_%&5UYRY_I[OG M+G_EKI*+M_BUW]UKW95^^>'.0W>ZJPJY _&]:F]U[VMM>T^8[>I;KXR(A5.^ MEZ&/N#P+?S!A@/DX8R(N$\_Z]RSFS&U:*MRP'O!6:87#^WS5=6_[ZN,]L55X M8N=!3WR$4ZWPRCM>9MNM:S>S9)/]ZNXU7>4+P=Q!E$]8-UO#M:_]J_A:/!M%L;G[MFWC$\\ MIKWJN_=9EQBQS8=J(DB[&JR=\0L5(3]FT"9O$KXYGJ79?/PE9)3C@MP3P5%\ ML?\RO/^+IS12H("SUQ.!!F&N6Q+$8_LBAIXBMHZB1AT(6 M(6SXS8MD8^V*H.?%W!._"RX+E5FM?NNN,7:M=K=WCS#R.^W6/8A:-)=T'O&P MPHE$O%AT@WW[IORW[_-0[]-Q>O<\\WS,KYMF?HDW5]+U\%R\3<$)\6W!J%". M.&:*,&)0$ZC2?A7]HQAJG271K)A$\T$,<:=W-;#[U]F'%V*T(EIQ/K@1KZ? +J!N M[XG1><'^FX&9$+A@_D(1DNXL%;B>MWR0?+^RUDD8-(1;7PC@JBQ$)J7C/\30 M.IA!B#866%@,.!:C+6%>P3R] M(M]Q/GS/Q0AN!>'%(#!6(]E[1YX#<5'X5;7Z0^D7^0:%!(LF7C*"5#3?JK:\ MZN;%X%-\*F_T "3#-U_&EYD81PM.K \VT5/:]W*MM5FLV7O.(ZC6O&;?NE#; MZ]WZYMVFO>W!22X\1G!"#-O%-R6%%)TA"O8NQ#"?2ZD62!-!^9CGXM.L(.@#;^;?8TI! M&HI79L-+Y>H\O8YNIC);(NWPK@:2T2@3T=[UEX(P+9)?ZE60.S V=R "236- M]'V4?%?V^=:+5&KS;,SYHR/)JYFHDOC?0CG,$;:T-!EU-!\-+;K">42^#-@[ M[J5ZT")#%E\/18J^HK!F<>VUY=[R1J\HOYD%CT"99Z@ "V&/:J[R3?"VYFL^$BEDM2,5"6K]WIW#4D14E/I2MO#>_$ M.$O$^NKO]V0ZBC\N]Q/WZ$($CK+C71KL"M&2BSC\A]^7C-][_##TJ@573"4N M6FMI^'17 S=ZF_[U@&"=0"3K!^(5Q9O/O.O,R,+\ WRVWI:?OS8"U2V9EE6 M]=**\_*'ZS _F_=-CKO7OS^C,2V*A.+EAW,WG+_Y5;%CGG__M==>%GDD")(* MQU!9GB#U1!@Y$ZVRR&[^%%XD B7 ME[U#J&&595\]48Y=9'#OA9$W5$^9/USJ2CZ\&/,V12/=*_E"++M_Z\UD&5#& MJ$MW?W!4?#++HR3YJH!S/@[3ZY*F?.L'(28[W*MBHZK',F\ZC50A(Q&VMBBG MR8RZW7V]B,9O$2Y7#[T5\M_SRD4^Q1=#%Q%6^T*5O^\TBZ[K']YWNVWN#4?B MWU;'&0U[(^ZYO=[(Z]C=7I-O;O&;ZK%& @UBN/$/G_?6JWK+YRW*V-Y"C!4S M+GR?\]'H_H5W3N>WQ3U5\?_V+9=FC#A$IT4_3Y_KJ\QM;E9ER[-,?"ZYNY') M5C(QYA:5W%,YH+W7X\DKW-'>1->>K[92T*>HKKG^?+_-VN#_7L5Z\J?-&6%U M*M5I?)X% M:K!%EO/(N?VD[?+!J-M8+==A#0ZT/W.+I/+ 4HXV-#T,2 X5#TQ$7#D,2WEVO2R2+"\P MH*(^LX-._<+*GAK"]OL8P)8CMGG#DE91)7%0)2%M>!B2&"@TV+_=9\(9R@R^>Y>%$ M;7\F-TJ2VT@$OMURXN=6"%Q=[OF4S?VRIKXZ2]+N7!@VY]<-B MWV3/SV="YL5^WA-OL9LUDX],YSMR7;_,?'OY(!&:4[O-1+.@V(-LFN3%.DJY M[9C\;[R60H]R8I_NZ/B_=1^ZT/<[D3SLR7SU!?G3]:;J86CH3SQ_E\9]F43V>I M^&[&[]FWJ=@PF-\\W> A6U$[6!>G'SQ@-G<>@^V@--T.ZNCX?X[.!^=')\?L M_$2\X?'[P]/#XX-#=C#X].FG&Z@L]L;Y+K\QX.6N_:C;9E[W/>^S0D[NEQ>Q<;J!Y MC3OU@%4[^5_;\IP!TMO#K'BN>K\A9]_YT!?W%3W0-S[?MR>6GWMJ]W[!(R]? MWO/G:N\7\3WARBLVDQ/7A^F>VEG1+W:5O]XE<<^7FQFEJ0+R7]+Q>K]=H M=SH-V^DWB\V.Q%.^CWEZM6OFGWMG>[>^U.VZC6Z_WW"[W4[Q)>G ZL(H\>>4 M;+ OGGR'@+^ZN-K)2R4,M]M)^+%S1>MDEYM,S7_Z*[T M=C M%_ZJ^%(>E:2.D&B,>1'AVC5>&-[U3TFCS01ECR;"!W$7-B%5,"-(S1NF=TG M>;'X5(0+PMEXO+0YI70WX3O'WKQ]#N9*4+&6W%-+M>\@$S&"VB]K]_C@OPZ-]R-_/B?8M8^* 0:J%N8;#^6)W!D5_U4?,S M33ZI;="DQMZI SA\^8V]>WU5>FFJO&.^\;"PNJMW52V911_Y.F9VF"Q,(2#10MLT,3//\_-6SSP@PA^5G#[BSIB1BA2 M;H*\)>^:;T;X/5%[WL\/9RD(I7QM['WC\]T:U8:&G)T+?P5019=[#W+K70-U'ML51'"??BH,.Y&T_*>.5 MY_!(=1T*$%R(F%$9J7I!3WB\8%\JNZZ[>BP.@9'M+>-V(4B:J5WW^)R(UARZ M8G"A;%.]ZU=^J:@K>K;K]TW$<^/Y"0Q77:C<44AVCWZ23A-I>H+9BPA'?#T+ MY_OO38M3G<0H(DHR+M2C6F^Q?:X,F'QY$,0W+YH5N]O)?3-EURPPH%Q@/KZ0 M^I%7%X?9J"WZ)[,XE%M#SR59>3;'TBD ]_>?!\DT+$[XR654IA"I!D0Q_RYW M[8RX.E.IZ-NN=O .8W7X4M%!F=LJ!U^ROU@>0I',HD"E#(8JC)4Y*[D/:C8;JJ1 7D1,:M0N*,C5/JAY M8JUZ$6%!_JR(M^8[V*;%;I3*'E2D*F585Z3YN5"9M-C8+TX>*_9K7>S7*:QX M:1?M^7#I]8KN=I9*$YLD,H192L\,N0ATOJD3OP3+Y,-G&1_-(GGC:^\14;F( MGB1TO'RQA?S<1?XKNW&NFC>_DPBU5!9&QB6R?Q?#A\G\6+%53YKN MO_$%3:\?,R?;?$O9F^>Y[0\9_-U- \QAXU<5%3DD=)J9276$AAHB'XLSSBZ@_\56B+%B, M_'.AE;$%&9.W$=_@P2,,YSI-MD(#5WFSZT,3'KJ7VDE8[@.ML%0P(>3SK]L6+BEWC/4>%'&QF_(D$8%FL;MFQ5C6>D/+.#"1.4([68:5KW.G2^^OLY?Y@\K8PZ8H30/+YCO_/Z? M61&;7G<44C_RT+Z%%L1GV8.M@S2>V6F\]R>G?PU.W[%/)R=_'!U_8&?G@_/# MSX?'YP]WZ_OAFZ/XJ@=4)[&H<%>-19L("\Z+?^P_WKS,95@CP7P4*0O9CS0=QDYW;>__JY.\HU%F>I M<&_!Q;/BSLSI#E99SIR<2V'7H,CWVWW752269V,&\@26JSO9ARN^=A6I77^_ MM?Q]MBN_L+-\V[<(Y.S8G069%?1WDY1\LEV++;CB?Y+ M;HLN8BGYJ]RE71B"_%&,YF+UPR(&D#]?E97D+]GLXD)\4-QG.I6CS9T5Q1DF MKN3\J[I,)A_EO[XD[TZAXF]>&LY3A%)V^9+?U?NJ(#"=1P7R>-)P='FG5G6MQP8A0'$2TB+PBT1#%%'8O%]-HDCM M4?_J9B%OE?1%;2^[BAA/_N?H7J$,:LXLZ#@P?)> M_-)?I3G4 U M'WY8Q9&VL7>5,2TR(/.(]T(YBSR;<)&6*S3&YPTX#W3F]"[.V;T>@67J8.OY MJ1!<6&(!6_]2GB^6%>R\+!RD&/7(/ZQL?-&.@?*S.ZU\\]971_->%V$O9%:F M.--*R#.+K@>'(Q[(?$W!"&G)+))Y@Z@8FJCP/U:Y?/7E4"96U)]6O,52-EF> M8#5/*8C>>MFBIL*[YZ2OH7QU7+$^HNE5L6[W1KT*+>.9#) M[F2J_I[ELJTN5#[HNB>_9>@W[RV8>*%25^J^$_PI@N9?)- MPDRAI>@8;@R@;C;-=9E>C ;4T]5K14FF/&E1<%\EO8!24HQ9BO@ZYK?"Z[_. M/BP_^_:CEQZXY*9^Y(43>2Z,: B5);Z0P5$NFNB.P8KA!\^O3I)3,8N7?N5Y M5AP6G7[C=_!Q0ZN!Z%/GH=#;,P"$7G]6#&3IT )8_$+EZ_&!9) MRB:+ "H-"YY)P$?>=WG>M]2H&/0(JL@\[ZX9F>AO[D:;CJ+".?B M>+::_Z=\*FXM)7XO@RN[V?CC"G$J+5)TY>^X<%>)%]=656I[D=(M3G\O!+R3 MQCL\V&/_F\P6HSD91HD>8MY=JIR*&C9&&2.\\,T@DBYSH3K->?A;!'E%*+44.U[/KE(QN#PC*U'E9,FFV60Z MQZD\-M*+91QU,?-2$73+:M_-8&[.YR)-+FNCWJQ(+:GP2W9!JI TBP-U/)7 MP/P0HY^%=XNZG!@<1!**U^F]6QZ\$EY3T7>JT#R6\<55#"=/0KXJ,-P8JJIH M4KV_*AC$B=)$4)YLF3(G8M GH9K*F)+,4C%ZCR%-L7 MG>'5$';.$_XCOR[U7 >UMWKV*/S*B][8DR.]W3!\L?KD1K8T3V(Y/%)$D*6A MZX'A4@2=+(*NHF<5P=FE/(-6_']A*V$VGPL@E2C# !%.J4?'&SHW*\;QKNI,UD=F)G\T'>:#G7N[B[\?^0V=- M^1VWQUO=P/6[?FOD=CT^#-I!TPE&;=X-1CTMSIIZSBJII5F[CEWQ?OT/VD') M^_B;HE/1-'4F].#Q342Z998)9 M@N3%;"EUNF\Q0UDT@_="BP,I[ET$T6H365.X45MR"8FTX0:ST5YH+[173=K+ M:.%@C&BORD1"^+5"NBTN5%XW<%\R&+O*D<'Y..6?/*Z;"NJ)NG MR=JM20>MM50>31U KIMCAH7WPRG]E2 MAM5MR5'5_DA@'&W&U=L^;=@G[).P?8*?&-)IISPX-YP;]JF_?3XI.,)P<85T M&YJ>\[C9%IA/!>'J,UD,[:57>Y5[0-'=,R1\G_/1J+2>XU3N.S.;;W%]M7%% MV8=TK*&&%1',>DZQ'&NHFVSFZ!<]==:K4F?=MFNU.Z6GN$JUMG6C7_GH"D_+ M69]'M+HB#2P"_*'"']>U+7D*@I:: W_ '_!':_YT>SVKZY:>905_P!^(#>S6 M%;NVU6XYEM-W]=0=P L"@4!:$ZC3L:UFIZ>GYLCRQ\C*[LG5"2UR)_@XX]DK M%&JVUWJT.A6T%]H+[07A8(QH+[W:B^0L"GM[8=H[=5; TGEZBVC-Z!A_.Z,C MG8?BE0XKVSW7LML=/35'=EB)M!9MBP"$2$'(:?]:S7Y+3]V!OL 0,*0_AMJV@)"-.5[&S+'8 M8O;^C$?R\%B+7?#XZJAJ+YB$<:A.;93G5%>5T >I-J:>2GG4ZUC-9I^R>LA" MIP;%7S*M"S94H)YVTW);I8^7P :P 6R@SH9NQ^J5/XP!&^K%!J.% _AT!)_= M<:P>A3TH03[ X0%Y 8<*U-/O6)TN@4WQ)"!(1P3UNTT]M4860&;.P'['IRGW0T_:6#'[>I*(-_JG M^$#_,H])6-(&/J[5ZJ%&6+T"#(IE@ 8ST.!8=A^+,:I7 -#PD+Q 0P7J<:RN M#314KP"CT6"T<.">CMSK6$ZS]&0-N P"NQ24!NR"/^"/_OS!N%/K MG'YIF?M3GN7IS,]GJ7@7#*CARKV<6Y'^03M 0F71]-IEZ83GB<,W\L_ES^(87#) UX>O6B61*% 1M& M0C7,GN:H/Y'6:RWG9A,R6+U&BW4MH1,R&!!.)\+95M\I?Q=&0N8*OH%OX)O! M?.NVP#?PC3C?:BHV(3\!UH%U"FH%UL$W\(V 7BLOKY2_-(>0N1I>E[FI,6=[ MU9?S)/6I,'J.% U:):*_B"H#;=:P> M!I, J]&-#_;08T_':5EV^DJLCMI>>/XK]9,+9*$TFBR1]$F/[>6V MIG^EL=NS>FY73\61I1CF2M"V"#"(%(-D;KY9_G0N, @, H/H**[:G4B;5L?(N'.M+5=[ &O2NZ"]T%YH+P@'8T1[ MZ=5>)*=7;'/SR3CG*<_R1;AF='R/$26M$:75:V-B!9):1G@2$*0C@FS+[I>_ MYA$( H* (#J*JS@*:E>PP2P0! 1!;)"WSN3M6FZWIZ?>0%X@" C2'T&VU>L@ M!6;,G(HM)NH_)5G&DIAQ+XTNF5"8>.HLS,;JW*ADQ (^S*LO4(%/3U1/U6>< MV*7/[#>"-34H[Y)I7:"A$O54=:3<4FY"+ MN58X%X/P?OE[LA*R5R =; /;C&2;TRI_620A:RV5;$;N0S@_.VC(1TG*YU46 MEGL_>.GG!P%F9M1VNRW+;F/>1_4*,"A" AO,8(/=LOK-TO=H!QO !K"!.AMZ M7H5.=2W4$S(8 $XGP+F6 MVR&]@3'X!KZ1,ACP32>^.6W+=DD?$@' 7 0NWH_ ==UXGJK8[G]\M=Y$K)7 MA7$ W_JS1^CA0-55.\NN:?7[Y<]"J0E_:K:>XKDLVXZL.]?Z= D) M6]-J-=H8;8PVUK^-:RHV3!MM;$@;FSZI9,I3EHV]]''32QKLK9>%?CU&0AB( MDQN(VWN5[TMK[# <:4!2!@#ZD*-/<\^M>K]_T ?T 7UJ21][KX,2*.@#X38F M'-!*1WG5UG?WFI@[#+36P0! 'W+T:>[UVIKKCRQ],+?DD8JJ55$'A3NT,=H8 M;:QU&]=4;)@VVMB0-L;[%\E5=E&(@&9E"## G:"^V%]H)P,$:T MEU[M13*!:&\O?*.Z>]PZ@3[1(@G9,M-F=%MM!;=KM;H4)^>5:K=Z57>U3U.8 M832 G7:PZU@=A^*&!( =8$?;: [[6#7M9H.Q;V? #O #F(3]!4P7D/&.VV, MWL%XP ZP,QYV':O5I#CAVW#853C;9HOU&NS(8B[L]$%:U^JVL?4]P2BM[K$8 M(%0G"#E8Q@L(U<( "&R$.IW 2% ",)M3#@0EI@&JR9LK]/17(,@[!.E-<6% M "'=(60[V(G8O$S]]A+U6%6S[0:CU:"\(!V-$>^G57O>$7[<_$9?) MPV+N7'GGNB#\MGCWSX/3#T?'C;?=V9?W7[P+_C;EWM>!^)]5BEI^T)?!A\/&V]/#P1^-P?OS0W%[ M+_KN768K;K=:Y_OC='&OMR>G[PY/&Y\.WY\W_CIZ=_YQKO2/ATKJPKY;UQVGX?H:4; M-WD[./CCP^G)G\?O&C?O)^QA_Z50SQU1[_FT. ;(YY$T3%_8Z^\[S4)U_W@M MW^T&3>ZV';O5\=WAR&\[[L@=]8>^(Z3P@F<5Y M>LD^_LOAFQ*'7X;H])3[2>R'4>C)&[!DQ(Z3N/%A,/C" MWH>Q)_[D1>PS][)9RC.H^"DJWOTS]F9!F// 8MY$6F\F;L+R<3++O#C(+,9_ M^'R:+QU/%GBY]\)D;9NUD<7]296NIG';K=Q;ED1A,$^]V2OS;NNZSY+%V(^* M [?DG^?CE'/V672[XXP=QD'YS7ZD!72E>F;Z^8*MF1+_Y[%G+E-"W!#SZ";\N"NL#BXJS;*JZ&[?O92?\Q< M&_X*?]5.>37T5W2OE-UU6<;]X;W#5%CU!JT:>8(5TFTQ);5BCN>VK6Y+,'": MC@..4N0HE ?G?KYSE[[)%^P3RH-SH^JTX M&7+_KH[;29/L#]\,@O_,,KDIX>';H_-W@U?[V6QZWWNKAA#?E^J/>6/,"SNQ M;\S\SB9>%(DFVGGC[;\4-WOSU)F@S\_FW:].35DH]30R65;XU,T\B*]3'/Q?C53R:<>7F>AL-9 ML:XW3\2+3R9)+.Z7^%_'223&]%GU'DUTNZQ?*6OFD1:S'MW2#S4#](S@PI/3N1M)VI(Q/4"K7,VX3:O?+_UP#".85?7Q ML&7/TSJ2D]YXEC/^8\KCC),TFDW5^$PZ1V,SBJL64U:O_.-B2S4XW6,NLXKK M$!OD):.X:D>UEDTT/@1Y:XV@FHH-\M:%O*[5IK#Z'>0%@B VR%LC\G8MMTMS MP@[(:R*"J$[EU\"004Y2Y+2M7@=Y6K/J3-NJ)JEE)KGW8U%/VN"B_V&QZ)^D M(8)OY(OBCFTY;9H!('5882(/A /X= 6?:[D=FBE'<.]YTD(X34P7W*M /4[; MLEV:56Z [WG20CA-3!?@JT ]K8[E8C\& O:A(QNP9 7@J@Q4N1U++O?UU-O(*_)"*JIV"!O?D)><)]54;)"W+N3M6$ZSJ:?> M0%X-$80U+""G&>1L6:TV@;-+C2)GU46G[926!O[?L[ P,E59"N.<7Z2JL-1( M>>3)$RW]),NS#2YM\;&T15?L48#;OW[I.;9#6C]D(889/Q .Y-.5?'T'\QRK M5X#18#!:.%!/1^JU:.8 ;WG20OA-#%=0*\"]0!Z!&Q#1RY@10N@A?&I7M2J MNK10]GJ64Y[EZ6B,;DP) $)N@(X"[I+C;ZM',4X*[M090 M3<4&=^O"W=V.BQP#<@R4ZTE8% -FDF*F8S6)[K=6-33UK5QMIS[UB5]X$FP#GRM7:L@J%B(#I&=1 .Y-.5? Z.M:I> 49S MP6CA #T=H8=PCXJ!& T'HX4#^4 ^D*]><,!R&)"KLLDQ39KE!NK4JKJH4/9R MF*/)U M366A@_EC\>:-EAA'A,@,*K4866BE';/J66C%)!6(3= 2PEQ1[;:OO MX(0ND)><)]54;)"W/N3MMD!>D)><)]54;) 7Y"6O-Y!70P1A20S(:08YY9(8 M+. VJWJUI24Q29:Q)&9!F EC\R*6C-@H_,$#YF49SS.21@0VD:^1=RAKABQC M,*\'PH%YNC*/M!!.$],%^2I0C]VGK!I [XG20CA-3!?0JT ]#LVM M:0&]YTE+N,Y O9H :)&'%L:H^E8 REZ_LJ@-<"^-+IE0I7B?69B-U8J69,0" M/LPWN*+E BM:S&,>[3JI;?5M1T^]D:4D9IA ;(*. /*2(B_E.!3LK36$:BHV MV OV:J YL-=D"-54;+"W+NQ%Q@'DU:+6A#4M("QEG.TTD8>]+H-EBN&A,N5P%TY OQN[;5[- \ZZ\V)_KI&-!!.#!/7^;U MNY25 ^*M+R@AJS=:.!!/2^(1W;01P'NRH(2,WFCA #PM@2>&M;TZ+XP!\YXD M'-;$@%G5!6D.$G&:U0W*7@MSDH]Y*NS*3R;<8C'/21H,2I]&ECYW'9K;:55= M]B00:YDU6P1B [ED%%2!]54;!"W-L1U ML1(%R*5:W7M.J\9H6(>.J(!"T? K>JXU>K1G+5"G5M5I_[+7CXRF$XC M\69QSO)4/%J\#'JEF2R)PH -(R$]LZ\QHUDP5B$W53P!UG:#N4AC/ ^J@&\2F["> NDY0 MM_N .J"N'=UJ*C:@KHM>JXW4.P1F6@'JH%L=%@H!RMKHM5(H=_I-(Y5*%LH5 MUB.7RK6;+CH&_YEE.0_8X=NC\W>##189O6J*C+XTE%>M:NO6I;3 5P!5PBW,>$ M5SK*JQ2N_:[5:O8TUR#@^D1I(9PYU@VXDH.KW6M:O3[H"KI2JT]56(4"'>DH MKU(ZMIM6O^]JKD&R<*RX@E3Z@K:;M:7Y)2@QH6Y/0+?5!J'V7NE[N%"SVJ?B M][?JPU*S)E1!;,IN KCK!O?NGK8!--A>#\C55&QJ;@*VZ\9VVP'< 7?:E*NI MV-3!.A')F+7.C9N: LVYP[H+-I;+9R-5NSW70YTBT MK67T<+!&/5J+](S:HTRINU$]=5/-=P? MOKF>;?CE[-4&)QG^IYADN/]R^(R)AMO):Y$S+R3TZBS"4^]7"H>V9NM-9I6F-%;.!BC7NUEM' P1KW: MRVCA8(QZM1>*+#6)[,NNO1SSG(6QGTPX\_(\#8>SW),3Y?)$B#29)+&X7^)_ M'2=1P-.L>N_4;EIIZ3O:&#!=M.U8O7Y+3\61W;\&V32(3= 10%TJU+5MJ]TJ M?6]%4!?X@=B@;EVIV[&M?J_T;0E 7> '8H.Z=:6N;;>L7I? P;C ;DWX0W7" MC@:&#&Q2P:8K=QCOZ*DXLM0TLP:8IS[T?F%^V MQ8;4JE?46S@8HU[M9;1P,$:]VLMHX6",>K47YI?58'Z97<4$LX'_]RPL1IO, MBP,QX,SY1>K)WQLICSRYZ-]/LCS;X*I_OYJCA0Q(BE"!I':9D7_]TG-L1U/- MD4V-(*$,L0DZ MA+BKU]!W.%P5UR?E13L<'=NG"WU=13:<"NR?RIJ=C +K!+ M6VG KH;\P;0U8-,,;")+8-#$-7M[,]=.>9:G,S^?I>)Q;'?(8SX*\^S%QJM4 M >$J%4CW&/54RK-=V[)MFD@K!UPOJI==QX@.PH%YNC*OY[8IZX9LI 8P0#A0 M3U?JM7HT,WZ@WO.DA7":F"ZH5X%Z=CLN1K> PIK"5;M2@8S5@5@5J,>QFEV: M.SE1C]2JKB24O2CF$[_P(I;Q/(]XL31>+HT9<;[)^@(G7%] C=7(&BM6P= ? MQYHU/P5B@[UD%%=M](FMFX%=H58#0: MC!8.W /WP+TZH0%+8L"MRB8E6LTN%B_K6$TH_9R8Z302;Q;G+$_%H^7>6]EE MEO/)QO?="@D7'5!L-;+8:G<=/;5&%H^8I *Q"3H"N$N*NZY-<[\P<+?6 *JI MV.!N7;AK]\%=<)><']54;'"W+MQU.UT]M0;N:@@@+(8!-\W@9J=/LTBE+S>K M+E]M:=^V),M8$C/NI=$E$PH33YV%V5@MCTE&+.##?(.5J@O"E2KPCGSQW;;Z M-LVZ$W5Z8=(0A /W=.4>E@52,1"CX6"T<" ?R ?R 0[U$P[DTY%\&.O2, \= MT8 %,N 6(C;]R%5UC:'L)3+'29QR?Y:J@^G#V$\FG.7>#^8%_YEEN3I'9H/% MAZ^$BP\HPQI9AJ4,0WU+L9C" K$).@+82XJ]8@#=HCF !GEKC:":B@WRUH6\ MB'K!7J*^5%.QP5ZP5P/-@;T:0@B+9L!.,]B)C(%1):VEBM^&ZU;GW@\63J:> MK];(Q$G<^# 8?%DN6Y5M1<,D#7AZ]>)9$H4!&T;";)@]S5%<+TU[E0)LU[:: MG=)WU2W?]IZ*L1?5PUW'"*^.P@&H1+17,5!!4] 4PCU7.-"4B/:J'5_W6AJK MCNP0&]2IHW! *A'M51N@]KH]C76'"'5]00E7="JLVP"'1+17\7B]]/J-X32L MN'Y3^J$]JH3# Q;S?+$BR+>[5KM9=41.FLV"[Y1 9]9J+VJV#CYKQ&>W;S5['6-U2Q;/1BXI>RZV MGR/1SK5N7$(BU7D*CM["P1CU:B^CA8,QZM5>1@L'8]2KO4C/E#7*F&HVT? = MCY-)&'NY?%0E.+E?8G*V@81<_<2&:9O?QC45&Z9M?AO75&R8MOEMK&F%L":F M:61UY"]UM!,/F"=>Q+O@5VNPQE[*Y>JKH9>%OL6J6("%I:4;4T^UY=RNU>J6 MOMT3H?6A5.Q#QTX/P@%\VH*O8W7*GV8(\-6+#48+!_!I";ZNU71*WSX)X*L7 M&XP6#N#3%'Q.&T/=ZA6@(QNJG?-"QO0 K@K4(X:JK6;IFP@; :ZZS:\*HUD> M?N-+Y_2H8D%CZ&4\8%/O4MMS>F@O-B.QT'H[>JT4?4[E2\TJ-5;=(SVS:OP0 MFZJ? .HZ0;VMY^[M@'J-Z%93L2GY":"N$]3[K:KW[ '403>(3=Q/ '6=H-ZQ M 75 G0C=J"ZQT-_. 66=H-RUD1.O4Q%QRV<^??_9*J- %A5Y8&E_V!.@N"$- M5CV-J]ON:JY!LJS#3*\Z"@?"$M-@U81U]#T?#X1]GK00SASK!F')$K;?!6%! M6 BW,>% 6&(:K)JPO4[5>5(0UE@(Z;@>#(0DIL&J"6D[3>;UL0TC9QU=\K])/;#*/2* M(3N.5-M:RVG%&KV%@S'JU5Y&"P=CU*N]C!8.QJA7>Y&N^AEE3#4KD+PK%M&P MPR]GA _LH;V@\%<]=59IE=?>:Y5>XS5\.2!R9A";H". N528V]QS:6XS#^;6 M&CXU%1O,K0%S[;U.Z>MIP%S !V*#N75EKKM7_BIQ,+>V\*$Z'T<#0P8SJ3"S MN=>C>9*3OLPT;%@1ANYOPB56/,"Q.S7[-1$HLA;?@/?\6RB1=%/!4/ M]?=?BIN]J=[7M4N)4(&D=GF1?_W2 M@HY44[$!WKJ %T$OV$O4EVHJ-M@+]FJ@.;!70PAA_AK8:08[D3 P:1*;O;U9 M;*<\R].9G\]2\3BV.^0Q'X5Y]F+C%:N <,4*J"._%_XN6:*5PZT7UF$J2U7,'XL_;[10 M-2)R%?=*0> U&F%^4(0#N33E7R8;T3".HPF@]'" 7O 'K ',M1,.& / MV /V:D0&+(H!MH MS;!5=26A]&-CIM-(O%FS'(!>"DZ4DW%!G@!7NIJ WA-)E!- MQ09X 5[J:@-X-200%L0 G,: D^:>D_J"L^HRUI9V<$NRC"4QXUX:73*A,/'4 M69B-U1*99,0"/LPW6+&Z(%RQ O!0@S>U!H^I0Q .V-,5>Y2+[B#?\Z2%<)J8 M+LA7B7I /AH&8C0OA$L/J,(:686E#$-]"[&8P0*Q M"3H"V$N*O63'SP!OK0E44[$!WKJ %T$OV$O4EVHJ-M@+]FJ@.;!70PAAR0S8 M:08[D3 PJ:"U5._;<-7JW/O!PLG4\]7ZF#B)&Q\&@R_+1:NRK6B8I %/KUX\ M2Z(P8,-(F VSISE*ZZ5IKU)^[5:QYJ]\TWLJQ5Y4SW8=X[LZ"@>>$M%>'O .X:P;VYU^H:JUG W1S*U51L:KX"N&L$ M=WNOB\@=<*=/N9J*3-X.[NV8 [X$Z(VJ%UE2,$M:-EF]_(B[S1)Q_Y\H[UP7AM\5[?1Z9K;C=ZA';_CA=W.OMR>F[P]/&I\/WYXV_ MCMZ=?YR/P3X>'GWX>/Z*.?*7^46G\J,;5\U_MIO-WZZN*N2_<=G!R:<3\9:_ M--5_*Y4B!A;3'\75\_L(+=VXR=O!P1\?3D_^/'[7N'F_'3D)4*CGCJCW?*I: MEOD\DE;F"TOZ?:=9J.X?9\C;+:<9<+?;:[ENT.^Y3M/M#)M!F[RBUV%/M[^R^'3YKP^<0ALBDZ36(UH]J3TW'?>I$7^YR=C3G/ M,RCT*0K=_3/V9D$HU&DQ;R)M-1,W8?DXF65>'&0O3%;KUA/D%4^4)Z&#!T5Z M>F#U'+VLZT[?Q\)!&K*'%1U=G'Q/O>FRL;D5NO"_9S%G;M.JOFJUKH#;J.0] M[KED"GTU4AG<5;GK.^[SR9"GS+6?Y++H4'XB4AD=RB:6^*WM@FO:[Y8PX#2= MTM>8UYJ;4-G:*H,C/\Z1;71 FG9 #PY]-V95A.@%D;8IDE&&1W9O@@UJ9W_X M9I!ES\AY/DKF+4SJ$ M5OBY*2=<:S5%C59G:JLII]LW4%?F+J$DT65 6#JF#H!6JRG;:KH= [55/D(K M''1O.MP<^'XQ%S'E/A>AYC#B%HMY3B_:I!E3UFW3:N)*Z39MJ^_0I!Q-EAF; M^H!(>K@LE+)"*:V^:_7+WV!(8X[5(CGX)>53+PP8_S'E<<:1$S1RH$:8B!35 MU;&ZW9:!VM(]%JQ5MJQ6PFH"!JAKO;&SU6GU#-26X;'H=B/.HSB;I6KQ=\K] M1+S"Y5*FD%[X23/(! ))*:5M==L86E: MM4K*&2QL]9X 2-/79LY;K MN-IJ1?=(4_L0JQ8BD7)9*&554K/9LYPN./9XL>NP#<^7-)F*%[I4ZZ+EDNCI M1$1L1->I$$IN:CN4(\Q&BNH2P9]#M!:DV^A60SI"V J$U80,4-=Z(&U;/9=F M]*D;2,U)$YZ(V-/+Q>V%5KR,%^;62$:-F?@%64,]!I:$05CI%*(VS1G?-)E& M%E$0:6LBD7)8*&7ENI56#Q1[O-AUR!A^2)+@>QA%] (SI >-QB!%==FV:[D= MFBM>=!O6:LA""%N!L)J@ >I:DZ1]J]4'20T(0SS"0F,0FJ'1HKJ:CE6KX-),/2BPEHET&HEK"9D@+K6 M!:G;PLZT!@2F&T3.<1(W%DN. S[BXJ> Y=X/S"349$Q)&(+5*:5G-?LX=:4J ML0V,B P4B93#0BDKR[M6VVEKJY3:A64EY@OCI;"-:J1&*%=8_<9()F'35&TZ M7/-6N7F#!:V>D\ I>EKT[&M?KOTP7WUVJQ=.+WQK16I!LI5 MA\-!,I,3#PIK=O:<]F,-NCH(_%JQ_VNHLK[;L_J=TK?E*5-QN@>RVD=P!HJD MO^.#E>NOX78=J]?LFZRXVH63)@R<:>5BM]0:UTIP]6F96IFA6<+6Q(S-&[ZG94N+ZL'M]J]?$+-2JQ":! M:8BDD\L"8;<0UNQ;W3;-)>0T$59J6'9_N+KU@$W%9GXRD<&9)TU+!6U#'O-1 M2'&F$*$I]=K.'R3<95!45Z=MMX(6=H-"0IJDO@LT6S8JS; M2!=9- AK$!B@KC4YVL3I7OH%J-L-0X]B/YEPM4?O8J8AN9B39F0)[I%2BDL3 M;30!AJ1:_40BY:U0R@JE="VWV=56)X:'857E"5>4=+F7QLGL>CW>);V0#6E" MHQE)45U=JTWT.$3=AK?(G$%8@\ =8&CYL>G6ZY6JW,B_+L;0= +/:O>__9) MFSG7C8YZZ\RVNIVJMW/:-KO6]TN4IP& MQ*4;9,ZG1-PYY^E$K9BVA&ZR["H8713?R06B-,--H)"44IQFVW*Q K$RL0V, MC P4B93+0BFK K=NQW([X-CCQ:Y#VO#AA=1Q$C>PF)K$Z*1VI*2HKJ[5M&G. M,==MZ*LA*B%L!<)J @:H:\U=P*T>T4W =0.I.3G$XZ5@,^ C+GX*U-)JTL5L MFK$F2$A**8[C:*L1W6-# X,B T4BY:Y0RLK"+\VB+TV&U2%W>%WT71RMYT=> M."$8I"%5:#04*:K+Z5B]\I>Y&#G$U1"-$+8"834A ]2U'DC;EFN7OAC&2)": MF2O48$,?FE$F$$A**72WCJ!),[)P@DA;$XF4PT(I*Y32MYJ@V!IBUR%16.Q_ M$UVE"TD7= GE"C>Q(I_BD$[?+2$H:M-V1.!8^M+FZK6I>\19J]R.R;-BQ^EL*I&2!9>X)(=T0RRO 0>#ZD'02>5'MLF*'9 MPM;$C,T)/,_RQ/\Z3J* I]E_,?[W+,PO7]%C+@+.-;2L8W1FH$A&&5ZIQ*OL M.&TQ"D]B\27!1'H,)#1S4]MI*E0PI8FZL"Z17K5;BW$ A*5@ZF H 76!H9I7 MVC<=90[$S:4A>1&;>F'0"&/F>]-0SH4D%W/2C"S!/E)*<9TF5D56*+:!H9"! M(I%R62AE)<=LJ]W&5K:/%[L66<&![\\FL\C+>< 2M=3;3R;3E(^YL*YOG$5) M1G"*#K*%1E.2HKIV;I:EZ%.'T?'/).A M!F4+3WGNA;$(/>4^D.(Q&=OUE@+2@(]"/\RWU]/HG#I\Y/8 ) :?5#BID\[Z MCF6W"(S7MZ,SI"7).8>!(NGD[]#9$P)*Q[&Z%$;EM""I6UA9VO"VV)0G6S$M MG%Z(22C'6?U.5"8AUU1MMN3)L';I.VQ4KT[=8]E:918-%K9Z3P"FZ6O3Z7>M MMH/=+$V;05#R;I9R(P\] NFJP^4@F0TC/K=U9\]I/]; MU>]4'?UN57&ZQ[G:!W@&BJ2_X_\*Q3WQS#37L7K-ON[J>T)PL9VX[F(Z[!PO'6-]/8GXC)/N,Z=*^]<%X3?%F_S>7#ZX>BX\?;D M_/SDLPKE!5$./AT.3I5_CE^S^17G)U^*/^^P,/A]Y]W9E_=?O O^-N7>UX'X MGU7P6G[0E\&'P\;;T\/!'XW!^_-#<7LO^NY=9BMNMYJ#^^-T<:^W)Z?O#D\; MGP[?GS?^.GIW_G%.MH^'1Q\^GK]BCOQE?M&I_.C&5?.?[6;SMZNK"OEO7'9P M\NE$O.4O3?7?2J6\8JWIC^+J^7V$EF[ M.Z+>\ZEJ6>;S2-J3+^SG]YUFH;I_.CX?N;VAX[>[K5;3Z_8ZO5:7N_U^.QAU M6EWG^<.V[V&0CQ<:&R6QZ&["?_C<6E:UUOI W= F)DY[W4[4YW'.TXWTHOO# M-P>IG*1_D,SB/+UD'[D7Y6/?2[G%CF)_;__E\$V)R0M#='K&+^2&I>R=EWO[ MV6QZGRSJ#<1WY7-CWACSPH+M&R:;3;PH$N^V\R;:?REN]@9M\I0VV?TS]F9! MF// 8MY$FGLF;L+R<3++O#C(7IBLUJV/XBI.5LYQ[SJ_41K4;C&_O:Z?+%F, MW:O0$<_'*>?LLZ#;.&.'<<"#ZM,@ZXJZB"TV9VMKMV:U6[ ]P_B<"FWO?[F7 M-A(A94/^!+N#W95C=V?\[YFX6_BT74S0LZZ0KB(K>M2&DUNRHG_/8L[M2 MT%/2[BDKIMRC#'1[E-O>FA!0#I1[OA6!KO6#F3U(;S!SMA?;2?*%H*7MYGO)O/)YQ-DJ3"?:J M&EMX0& MAR+/WASB81NHI#]\5!O1\.1MD5>+/7;1QO!#G=H(?FA^&\,/Z;<1 M_!!MC#8FW<95GI"YO4K7\2S-N-IW?1!%(0_86>Z-1N+1U;O!BIE,3Y^%H_$V MYNMHIE>E9KJN;;5:-(_BW>[DA9(V)=](6G[[2FY5:83];HWM[[?J92>9*B?3 ML.B2RM6,:W]1Z M$;E2[MANZ<>HP>AA]-4:_6Z+LFJV;/,OGF3TA-+\I51_OHPOL] /O;BRS/\F MECAOJF2&LZ;O@QA%O3J.9=M:'CI=9HFWTD+%5F:.E#(\HVCPU&MKU1@SJ>!6 MBRD;^H,/';5.';7=MCIN']V-9MT-]<(-NAMT-^ANT-W<&1>ZEMW>WMYAZ&XP MND%W8UIW8P#W6M1+7/ @>!!I#R)?,*O&@[0KI=VJI&GO6K=B]B"9#2,^#]J= M/:>]_GBH1G/C-JR\:J?/M5VKW2F]GZ_&_LA7MZB/\BK,^#:W-\63_M034A$G M.C]T?F9T?JYK6SUG>Y.7 7: '6#7EDT NZY@[_9Z5MI-&3+W*@E*%%*0.GW%2I-AJ[XM6@-ZA?>\',GZ0VF+E>[04S M?Y+:8.9H+[27;GL(WQI&E#(-\2")\S0"KN/]E_*6[VIAK;,NW4'&SV3QG( M6LP:1AO#G>!.<">XD\ZJACNAC='&I-N8T!YU.(JF3G/.M"EQ][M6NU/GJ1U( MG:^O1Y+]KH'"@:::T=1M6TYO>Y.& ),GJ0TP 4PTA(EM-RV[N;T5S*#)D]0& MFE#VF6Z=QS*8IEY5PU8[3=VFOIT5YJD_D!G$Z178I92&7HGN-69;CE/ZDDM* MYDH^MXE:,Y401;,ZI/Z^B:Y$IZZDW=%VMVO@$#@$#C75*U$K= MM!'Y94Q064-MJ-4#J;HBU6U;O58'1-'4Z4"4A^0%42I0CVW;5J\#I.CJ=35% M2L6S:+?G+_1'-:12C##ZN_)N:Q;M]J8&T#=ZW9."6J3BL8T:BL.4R:Q990MM M#'>".\&=X$XZJQKNA#9&&Y-N8SK#/!+JV&C.5LLA&U+=:ZA-[ZQ?_=H+9OXD MM<',]6HOF/F3U 8S1WNAO70;1E2RY\I!DDZ3U,LY2\1+CKD7;/!,G_BY9_IH ML,*AQA.F*"K.[EKMGDM9<=AI!6DLI"JW*C9P7QOTR-N@'TZC8*)BFAVON.MO;B8A"3U#NS&SX4"U]J$=9:9JY$*%T]09] MZQV?IMP//774O#Q#T)LDXHW^*3Z@;3T(N(FNG7*M5H_Z9DM&I']1JE]#;7J7 M?LDX!8A:@7H4A> *4"]3A6UP90=/6YF@*EV@TAVM2S*?1R M)K!Z[:W>@=5KG"DL)3\_\/^>A85YJ11B&.?\(E49Q$;*(R_G4K@LSS8XW]7' M?%>3 V.:BNLYMD-:L-^M8IS_)TYN>S5#R. M[0YYS$=AGKW8>&8ZT"(SC?"=:L'-MFQ[>XD'#6INF)6B:=A0T_H\:$J7ICUW M>ZL(@9,GJ0TX 4YTQ4FK5T8*%3A90VW "6%_<5SJ^\.1R[[ Z'4W>M>M\\F! MNJ<<2TGT'TVF7IA.>)PS?RS^S#>9@!Q5DX <)FG TRO1LR0* S:,A#J9/9SI[#GM]4/XZGSN5\V55VEQL-NS>FY7![*Q.J1?EAZU5:EY"P*(A34;6IU3RT,=P) M[@1W@COIK&JX$]H8;4RZC>D,\TBH8Z,Y6RV';$AUKZ$VO;-^]6LOF/F3U 8S MUZN]8.9/4AO,'.V%]L(PHOP67GL)YG*=S^=QSM.'"Z5+!F,_RF+6?< C57H6 M_F"?DS@?9^PP#GA0/1O6%72[-=M'M66U['F&Z;4U5AGL33][JY)T_\N]M)$( M*1ORI^KM#C$08B#-6O@9GO^HU.N6//_?LY@SMVEMS>>WVX5L22N:&E*57VMF]A5TWB8%P/>ZLEW?RQ%U_PZBT.(WJ,Z$FW M\"8VEMQV#F!+8'6:SO;6)2.0KD=7(SAL1G#8ZP=VKS::#@&0&9@ M>\',GZ0VF+E>[04S?Y+:8.9H+[27YL.(4C:F..7?>#R;'\>1\?1;Z//L536V M@)WG:*F:AD-N"Z#8]T6S-H8[P9W@3AMK8[@3W GNA#9&&\__4-6PS]Y>^>AX MEF:<>7' !E$4\H"=Y=YH)!Y=O1O@!)SU-5/MB5M6J]^UFDZ=#R_0(=N]?26W M*CUEJ?2S.@G9'TZ,(=ZPZ)3*U4S'Z5OV%@^1 I$?0>0V9?,$D=<7%#7!)[07 MIBH\26UZF[GAW:OM]BCK!FQ?7U"P_G%ENG0W-9DS1(%54+7Y[E1* MDIEB?]3:7@B!#JE.'E032M)9NTA"'1L*^JE-;S,W?H8M]3D>8#O8CJPDT1;6%/%4W'^R_U+<[ WA M*35:#FTPQY,>D#%#3;,VACO!G>!.&VMCN!/<">Z$-D8;S_] 9;\7;/1U<$9!BE"V!;OK8M,^&GHENMN.8_5[I>\ M1\E+4+^C$E%J5MO1WS?1E>C4E=A6O[^]->L 8M46K#T0T<9P)[@3.;&U MZ^C:U'=FP0ZE>GA032A)9Q$/"7402^6;-,C2I@KDV$VKTZ[S+C H':^O1T)^ M1;**1L8IP-0*U--M69T^YESIZG0DB5*_]H*9/TEM>INYX3V#W:-^IDQM\C*$ MC-XH2-')L2#S)N^+C4Q*4S4-!T0B&VT,=X([P9TVV\9P)[@3W EMC#:>_X'( M,(^$.C8ZD-=RR(8D[1IJ0[Y*K_:"F3]);3!SO=H+9OXDM<',T5YH+]V&$96L MT#](TFF2>CEGB7C),?>"#>ZJ'S]W5WT-U@34>$(;1<6YKM5SNY05AW7Y2&,A M5;E5L8'[NN#>Z5E.=WNX!]/HV:AF3$,;PYW@3N3$UJZGVW6PMG[5J.8%J4G< M6OA033A)*)6W07V\X].4^Z&G#L*4)YQXDT2\T3_%!Y6[ A:(ZK@,J&,Y3>K= MBQ&I,90QUU";WF4Q,DX!HE:@GI;5:F]O:26 \B2UZ0V4^K47S/Q):M/;S WO M&';=/F7=;#G0II6M(63U1E&*4.:EE(3

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